ANNUAL
REPORT
2019
A VITAL LINK
IN HEALTHCARE
Company Profile
2019 Financial Highlights
Andlauer Healthcare Group Inc. (TSX: AND) is a
leading and growing supply chain management
company offering a robust platform of
customized third-party logistics (“3PL”) and
specialized transportation solutions for the
healthcare sector. Our 3PL services include
customized logistics, distribution and packaging
solutions for healthcare manufacturers across
Canada. Our specialized transportation
services, including air freight forwarding, ground
transportation, dedicated delivery and last mile
services, provide a one-stop shop for our clients’
healthcare transportation needs. Through our
complementary service offerings, available
across a coast-to-coast distribution network,
277.0
we strive to accommodate the full range of our
clients’ specialized supply chain needs on an
integrated and efficient basis.
Revenue
(C$mm)
290.0
40.9
Operating Income
(C$mm)
Revenue
(C$mm)
Operating Income
(C$mm)
EBITDA (C$mm)(1)
and Margin (%)
Net Income and
Comprehensive Income
(C$mm)
277.0
290.0
45.0
40.9
70.6
64.4
28.2
30.3
23.2%
24.3%
2018
2019
2018
2019
2018
2019
2018
2019
EBITDA (C$mm)(1)
and Margin (%)
Net Income and
Comprehensive Income
(C$mm)
45.0
70.6
64.4
28.2
30.3
2019 Operational Highlights
/ We completed the construction of our new facilities
23.2%
24.3%
in Calgary, Alberta, expanding our logistics and
distribution footprint by 23,000 square feet and
significantly increasing capacity in our specialty
transportation segment;
2019
2018
2018
/ We secured a lease on a new 220,000 square-foot
facility (commencing July 1, 2020) in the Greater
Toronto Area to service a major new client and to
add capacity for future growth; and
/ We successfully completed our $172.5 million initial
public offering of subordinate voting shares and
commenced trading on the Toronto Stock Exchange
on December 11, 2019.
2019
2018
2019
2018
2019
(1)
Defined as net income (loss) and comprehensive income (loss) for the period
before: (i) income tax (recovery) expense; (ii) interest income; (iii) interest
expense; and (iv) depreciation and amortization.
33FACILITIES
1.8MSQUARE FEET
OF CAPACITY
To our shareholders,
On behalf of the Board of Directors
and management of Andlauer Healthcare
Group Inc. (“AHG”) and our team of over
1,400 employees and owner operators
across Canada, I am pleased to present
AHG’s 2019 Annual Report, our first as a
publicly traded company.
Michael Andlauer
Chief Executive Officer
Our initial public offering (“IPO”) on the Toronto Stock Exchange
was successfully completed on December 11, 2019. The IPO
comprised the issuance of 11.5 million Subordinate Voting
Shares (“SVS”) at a price of $15.00 per share, which included
the subsequent exercise of an over-allotment option,
resulting in total gross proceeds of $172.5 million. Today, AHG
has a total of 12.5 million SVS issued and outstanding, in
addition to 25.1 million multiple voting shares that are held by
Andlauer Management Group, providing strong alignment
with holders of SVS.
33 facilities from coast to coast. None of our competitors
can match this national network. We provide, directly or
indirectly, specialized transportation in Canada for 22 of the
top 25 global pharmaceutical manufacturers and manage
the finished goods distribution of approximately $7 billion in
pharmaceutical product sales. We continue to demonstrate
strong client retention with an average client relationship of
more than 15 years across our top 20 clients, a testament
to the professionalism and strong employee culture that we
have fostered.
AHG’s 2019 financial results demonstrate our continued
success in generating growth by leveraging our unique set
of competitive strengths and national platform to provide
specialized supply-chain solutions to the growing healthcare
industry in Canada. Year-over-year revenue increased 4.7%
to $290.0 million and operating income of $45.0 million
was 10.1% above the 2018 level. Net income increased 7.7%
to $30.3 million and 2019 EBITDA was $70.6 million, 9.6%
ahead of the previous year. We generate strong and stable
EBITDA margins, and were able to increase EBITDA margin
to 24.3% in 2019 from 23.2% in 2018.
These results are consistent with our recent history. By
offering a diversified platform of healthcare transportation
and logistics offerings, we have successfully grown our
revenue at a compound annual growth rate of approximately
10% since 2010 and are today very well established in Canada
with over 1.8 million square feet of healthcare space across
Our success is built on a platform of supply chain
companies that deliver discrete service offerings, operating
in the highly regulated and stringent healthcare industry.
This platform of services ranges from specialized logistics
and distribution, packaging solutions, air freight forwarding,
ground transportation, and dedicated and last mile delivery.
While our customers are primarily in the pharmaceutical
manufacturing business, they also include producers of
nutraceuticals, medical devices, and consumer and animal
health products.
We are differentiated in a highly fragmented market by
four established competitive strengths that span all the
services we provide. First, end-to-end validated temperature
management. Our distribution facilities are GMP licensed and
temperature mapped. We have over 1,200 individuals trained
and educated in the movement of healthcare products.
Second, regulatory compliance and quality assurance.
As I write this letter, the global community is battling
the COVID-19 outbreak. As a supplier to the healthcare
sector, AHG is part of the solution and our great team
is doing everything we can to support the healthcare
needs of people across Canada. AHG truly is a vital link in
Canadian healthcare.
In closing, I would like to recognize the contributions of AHG’s
associates, management, and directors in our early days as
a publicly traded company. We also wish to thank you, our
shareholders, for your confidence and support. We look
forward to regularly updating you on AHG’s progress as we
continue to advance our growth strategy and build value for
all stakeholders.
Yours in health,
Michael Andlauer
Chief Executive Officer
Letter to Shareholders (continued)
Many of our clients’ products are highly regulated and
they require us to meet those regulations as well. Third,
technology-enabled visibility and temperature monitoring
capability throughout the supply chain. And fourth, security.
Given the value and importance of these products, security
is of upmost importance to our clients. As an example,
we maintain Health Canada compliant vaults for the
management of narcotics and controlled drugs.
Looking ahead, we are well positioned in a very attractive
market. Spending on healthcare logistics and transportation
has been outpacing GDP growth in Canada and this growth
is forecast to continue, driven by demographic trends.
Further, there is an increasing number of healthcare and
adjacent products with unique logistical needs, including
biological pharmaceuticals, narcotics, medical devices and
vaccines. Ever-increasing industry regulation also increases
our clients’ requirements for specialized supply-chain
solutions and represents a significant barrier to new industry
participants. And, demand for distributed ancillary services
is increasing as healthcare companies focus more and
more on their core competencies like R&D and marketing.
Our successful initial public offering at 2019 year-end has
positioned us well to advance our three-part growth strategy
that will further enhance our market-leading position. We
intend to strengthen our clients’ connection to our platform
by broadening our service offering, increase our capacity to
attract both new clients and new business, and expand our
platform through acquisitions. We are confident that AHG
will continue to produce growth and stability, while providing
a reliable dividend to shareholders.
ANDLAUER HEALTHCARE GROUP INC.
Management’s Discussion and Analysis of Financial Condition and Results of Operations for the
fiscal year ended December 31, 2019
March 12, 2020
TABLE OF CONTENTS
Cautionary Note Regarding Forward-Looking Information .............................................................................. 1
Basis of Presentation ............................................................................................................................................ 2
Non-IFRS Measures ............................................................................................................................................. 3
Overview ............................................................................................................................................................... 3
Summary of Factors Affecting Performance ....................................................................................................... 5
How We Assess the Performance of Our Business .............................................................................................. 8
Selected Consolidated Financial Information .................................................................................................... 12
Reconciliation of Non-IFRS Measures ............................................................................................................... 13
Results of Operations ......................................................................................................................................... 13
Summary of Quarterly Results .......................................................................................................................... 19
Liquidity & Capital Resources ........................................................................................................................... 19
Contractual Obligations ..................................................................................................................................... 23
Off-Balance Sheet Arrangements ....................................................................................................................... 24
Seasonality .......................................................................................................................................................... 24
Financial Instruments ........................................................................................................................................ 24
Related Party Transactions ................................................................................................................................ 25
Critical Accounting Judgements and Estimates ................................................................................................ 29
Significant New Accounting Standards Not Yet Adopted ................................................................................. 30
Accounting Classifications and Fair Values ....................................................................................................... 31
Risk Factors ........................................................................................................................................................ 31
Outstanding Share Data ..................................................................................................................................... 32
Disclosure Controls and Procedures and Internal Controls Over Financial Reporting ................................... 33
Additional Information ...................................................................................................................................... 33
- 1 -
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
All references in this MD&A to the “Company”, “AHG”, “us”, “our” or “we” refer to Andlauer
Healthcare Group Inc., together with our direct and indirect subsidiaries, on a consolidated basis, which
is referred to as “the Group” in the Company’s financial statements. Additionally, all references to “Q4
2019” are to the three months ended December 31, 2019; “Q4 2018” are to the three months ended
December 31, 2018; “Fiscal 2019” are to our fiscal year ended December 31, 2019; “Fiscal 2018” are to
our fiscal year ended December 31, 2018; and “Fiscal 2017” are to our fiscal year ended December 31,
2017.
This management’s discussion and analysis of financial condition and results of operations (“MD&A”) for
the three months and year ended December 31, 2019 should be read in conjunction with the Company’s
audited annual consolidated financial statements for the fiscal year ended December 31, 2019, along with
the related notes thereto. This MD&A is presented as of March 12, 2020 and is current to that date unless
otherwise stated.
Cautionary Note Regarding Forward-Looking Information
This MD&A contains forward-looking information and forward-looking statements (collectively,
“forward-looking information”) within the meaning of applicable securities laws. Forward-looking
information may relate to our future financial outlook and anticipated events or results and may include
information regarding our financial position, business strategy, growth strategies, addressable markets,
budgets, operations, financial results, taxes, dividend policy, plans and objectives. Particularly,
information regarding our expectations of future results, performance, achievements, facility expansions,
leases, platform expansions, acquisitions, public company costs, payment of dividends, prospects, financial
targets or outlook, intentions, opportunities or the markets in which we operate is forward-looking
information. In some cases, forward-looking information can be identified by the use of forward-looking
terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity
exists”, “budget”, “scheduled”, “estimates”, “outlook”, “forecasts”, “ projection”, “prospects”,
“strategy”, “intends”, “anticipates”, “does not anticipate”, “believes”, “commencing” or variations of
such words and phrases or statements that certain actions, events or results “may”, “could”, “would”,
“might”, “will”, “will be taken”, “occur” or “be achieved” . In addition, any statements that refer to
expectations, intentions, projections or other characterizations of future events or circumstances contain
forward-looking information. Statements containing forward-looking information are not historical facts
but instead represent management’s expectations, estimates and projections regarding future events or
circumstances.
Such forward-looking statements are qualified in their entirety by the inherent risks, uncertainties and
changes in circumstances surrounding future expectations which are difficult to predict and many of which
are beyond the control of the Company.
This forward-looking information and other forward-looking information are based on our opinions,
estimates and assumptions in light of our experience and perception of historical trends, current conditions
and expected future developments, as well as other factors that we currently believe are appropriate and
reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking
information, there can be no assurance that the underlying opinions, estimates and assumptions will prove
to be correct.
Forward-looking information is necessarily based on a number of opinions, estimates and assumptions
that, while considered by the Company to be appropriate and reasonable as of the date of this MD&A, are
subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual
- 2 -
results, level of activity, performance or achievements to be materially different from those expressed or
implied by such forward-looking information, including but not limited to:
the Company’s ability to execute its growth strategies;
the impact of changing conditions in the healthcare logistics and transportation services market;
increasing competition in the healthcare logistics and transportation services market in which the
Company operates;
volatility in financial markets;
changes in the attitudes, financial condition and demand of the Company’s target market;
developments and changes in applicable laws and regulations;
the Company’s ability to source and complete acquisitions;
the Company’s ability to retain existing clients and develop new clientele;
the Company’s ability to retain members of our management team and key personnel;
increases in driver compensation and the ability to attract and retain employees;
the Company’s ability to expand into additional markets; and
such other factors discussed in greater detail under “Risk Factors” in this MD&A and in the
Company’s annual information form dated March 12, 2020 for Fiscal 2019 (our “AIF”) which is
available on the Company’s profile on the System for Electronic Document Analysis and Retrieval
(“SEDAR”) at www.sedar.com.
If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying
the forward-looking information prove incorrect, actual results or future events might vary materially from
those anticipated in the forward-looking information. The opinions, estimates or assumptions referred to
above and described in greater detail in “Risk Factors” should be considered carefully by prospective
investors.
Although we have attempted to identify important risk factors that could cause actual results to differ
materially from those contained in forward-looking information, there may be other risk factors not
presently known to us or that we presently believe are not material that could also cause actual results or
future events to differ materially from those expressed in such forward-looking information. There can be
no assurance that such information will prove to be accurate, as actual results and future events could
differ materially from those anticipated in such information. Accordingly, investors should not place undue
reliance on forward-looking information, which speaks only as of the date made. The forward-looking
information contained in this MD&A represents our expectations as of the date of this MD&A (or as of the
date they are otherwise stated to be made), and are subject to change after such date. However, we disclaim
any intention or obligation or undertaking to update or revise any forward-looking information whether as
a result of new information, future events or otherwise, except as required under applicable securities laws.
All of the forward-looking information contained in this MD&A is expressly qualified by the foregoing
cautionary statements.
Basis of Presentation
Our consolidated financial statements have been prepared in accordance with International Financial
Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and
are presented in thousands of Canadian dollars unless otherwise indicated.
As described in additional detail in the audited financial statements of the Company, our financial
statements are presented as consolidated financial statements. AHG’s acquisition of the AHG Entities (as
defined below) in connection with the Company’s initial public offering (“IPO”) was a business
- 3 -
combination involving entities under common control in which all of the combining entities are ultimately
controlled by Andlauer Management Group Inc. (“AMG”). This method results in our financial statements
being restated for periods prior to the date of obtaining common control, to reflect the combination as if it
had occurred from the beginning of the period that the entities were under common control, regardless of
the actual date the common control transaction closed.
Non-IFRS Measures
This MD&A makes reference to certain non-IFRS measures. These measures are not recognized measures
under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be
comparable to similar measures presented by other companies. Rather, these measures are provided as
additional information to complement those IFRS measures by providing further understanding of our
results of operations from management’s perspective. Accordingly, these measures should not be
considered in isolation nor as a substitute for analysis of our financial information reported under IFRS.
We use non-IFRS measures including “EBITDA”, “EBITDA Margin”, “EBITDA less Leases and
CAPEX”, “EBITDA less Leases and CAPEX Conversion” and “EBITDA less Leases and CAPEX
Margin”. These non-IFRS measures are used to provide investors with supplemental measures of our
operating performance and thus highlight trends in our core business that may not otherwise be apparent
when relying solely on IFRS financial measures. We also believe that securities analysts, investors and
other interested parties frequently use non-IFRS measures in the evaluation of issuers. Our management
also uses non-IFRS measures in order to facilitate operating performance comparisons from period to
period, to prepare annual operating budgets and to determine components of management compensation.
For a description of how we define these non-IFRS Measures and an explanation of why the non-IFRS
measures provide useful information to investors, please see “How We Assess the Performance of Our
Business – Non-IFRS Measures” below.
For quantitative reconciliations of net income and comprehensive income to EBITDA and EBITDA less
Leases and CAPEX for Q4 2019, Q4 2018, Fiscal 2019 and Fiscal 2018, please see “Reconciliation of Non-
IFRS Measures” below.
Overview
AHG was incorporated under the Business Corporations Act (Ontario) on November 12, 2019 with its head
office located at 100 Vaughan Valley Blvd, Woodbridge, ON L4H 3C5. The Company’s subordinate voting
shares (“Subordinate Voting Shares”) are listed on the Toronto Stock Exchange (the “TSX”) under the
stock symbol “AND”.
Initial Public Offering
On December 11, 2019, we successfully completed an IPO of 10,000,000 Subordinate Voting Shares at a
price of $15.00 per share for gross proceeds of $150,000,000. The underwriters in the IPO were granted an
over-allotment option (the “Over-Allotment Option”) to purchase up to an additional 1,500,000 Subordinate
Voting Shares at a price of $15.00 per Subordinate Voting Share, which was fully exercised on December
16, 2019, and raised additional gross proceeds of $22,500,000.
In connection with the IPO, we completed a series of reorganization transactions (the “Pre-IPO
Reorganization”), including the settlement of certain outstanding related party balances, the creation of a
new Ontario corporation, 2721275 Ontario Limited, and the settlement of the AHG Employee Benefit Plan
Trust (the “Employee Trust”), for the benefit of certain executive officers and employees of the Company
- 4 -
and the AHG Entities. In addition, on December 11, 2019, we completed the acquisition of a number of
entities including Associated Logistics Solutions Inc., Credo Systems Canada Inc., 2186940 Ontario Inc.
and their respective subsidiaries (collectively, the “AHG Entities”) from AMG in consideration for the
issuance of 25,175,000 multiple voting shares (“Multiple Voting Shares”, and together with the Subordinate
Voting Shares, the “Shares”), and two non-interest bearing promissory notes in the aggregate principal
amount of $200,000,000. See “Related Party Transactions.”
In connection with closing of the IPO, we also entered into credit facilities (the “Credit Facilities”) with
Royal Bank of Canada and Canadian Imperial Bank of Commerce, comprised of a revolving facility in the
aggregate principal amount of up to $75 million (the “Revolving Credit Facility”) and a term facility in the
aggregate principal amount of up to $25 million (the “Term Facility”). See “Liquidity and Capital
Resources – Credit Facilities”.
Our Business
We are a leading and growing supply chain management company with a platform of customized third-
party logistics (“3PL”) and specialized transportation solutions for the healthcare sector. We offer services
to healthcare manufacturers, wholesalers, distributors and 3PL providers, among others, through a
comprehensive platform of high quality, technology-enabled supply chain solutions for a range of products,
including pharmaceuticals, biologics, narcotics, precursors, active pharmaceutical ingredients, over-the-
counter, natural health, animal health, consumer health, cosmetics, health and beauty aids, and medical
devices. We integrate our uniquely designed nation-wide network of facilities, vehicles, personnel and
technology systems into our clients’ businesses to offer holistic solutions that span all of our clients’
shipping needs and satisfy the requirements of the highly regulated Canadian healthcare industry. We
differentiate our service offerings and deliver value to our clients through our competitive strengths in
temperature management, quality assurance and regulatory compliance, technology-enabled visibility
throughout the supply chain and security. We are committed to developing and expanding long-term
strategic relationships with our clients to provide improved operational efficiencies and access to value-
added services. Within our healthcare logistics and specialized transportation operating segments, we offer
robust solutions specifically tailored to the healthcare market and generate revenue across five principal
product lines: logistics and distribution, packaging solutions, air freight forwarding, ground transportation,
and dedicated and last mile delivery.
Management believes we are Canada’s only national third-party service provider focused exclusively on
delivering customized, end-to-end logistics and specialized transportation solutions to the healthcare sector.
Our 3PL services are provided under our Accuristix brand, through which we provide customized logistics,
distribution and packaging solutions to various healthcare manufacturers. Our specialized transportation
solutions are offered under our ATS Healthcare brand, where we provide a one-stop shop for our clients’
healthcare transportation needs through our specialized air freight forwarding, ground transportation,
dedicated delivery and last mile services. We believe we are a national leader in the Canadian healthcare
logistics and specialized transportation markets we serve.
In our healthcare logistics segment, we serve as an extension of our manufacturing clients, leveraging our
infrastructure and expertise to manage their supply chain activities, allowing them to focus on other
strategic priorities such as sales, marketing, research and development. We focus on serving our logistics
clients as comprehensively as possible and incorporate multiple services from all of our related product
lines into our customized logistics solutions.
In our specialized transportation segment, we leverage our national infrastructure to offer coast-to-coast
delivery, including specialized facilities, multiple modes of transportation and flexible capacity to
- 5 -
accommodate the full range of our clients’ logistics and/or transportation needs on an integrated and
efficient basis. By combining multiple service offerings, we can effectively provide managed and monitored
movement of our clients’ temperature sensitive and valuable products through a closed-loop nation-wide
system.
We differentiate our services and deliver value to our clients through four competitive strengths:
temperature management, quality assurance and regulatory compliance, visibility throughout the supply
chain and security. These capabilities are deployed across our nation-wide network of 28 secure,
temperature-controlled facilities and the five third-party owned cross-docks that we operate from, by our
team of highly-trained employees who are passionate about client service. Our security, information and
monitoring systems, as well as our temperature management expertise, allow us to meet and exceed Health
Canada guidelines and regulations, ensuring the integrity and quality of our clients’ temperature sensitive
healthcare goods and data.
Additional information about the Company can be found on our profile on SEDAR at www.sedar.com or
on our website at www.andlauerheathcare.com. Our AIF is available on our profile on SEDAR at
www.sedar.com.
Summary of Factors Affecting Performance
We believe that our performance and future success depend on a number of factors that present significant
opportunities for us. These factors are also subject to a number of inherent risks and challenges, some of
which are discussed below and in the “Risk Factors” section of this MD&A and in our AIF.
Service Offering
We believe that offering a platform of services designed specifically for the healthcare sector puts us in a
unique position as a provider of supply chain solutions. Our competitive strengths in temperature
management, quality assurance and regulatory compliance, visibility throughout the supply chain and
security allow us to provide healthcare clients with specialized, integrated, end-to-end supply chain
solutions. We generate revenue across five principal product lines: logistics and distribution, packaging
solutions, air freight forwarding, ground transportation, and dedicated and last mile delivery. We believe
our service offerings complement one another and allow us to accommodate the full range of our clients’
specialized supply chain needs on an integrated and efficient basis.
Relationships with Manufacturers and Distributors
We believe that our market position is strengthened by the desire of our clients to increasingly outsource
their supply-chain management to specialized service providers with the expertise and experience to
effectively and efficiently optimize their product distribution to clients. We are committed to developing
and expanding long-term strategic relationships with our clients to provide improved operational
efficiencies and access to value-added services. From manufacturers to distributors to retail locations to
front doors across Canada, we store, transport and monitor and manage the temperature conditions of a
range of healthcare products. Our trained personnel comply with healthcare industry regulations and best
practices.
New Development Projects
We secure client contract wins as a foundation for growth and then add incremental warehousing and
distribution square footage through capital efficient leases. Given the required lead-time to build and certify
- 6 -
facilities, as we secure new major client contracts, we typically strategically invest in excess capacity in
anticipation of growing client needs, as well as new client opportunities, which enables capital efficient
growth. We have followed this strategic approach in the past at our Brampton, Ontario location, where we
constructed a new 267,000 square foot facility in 2016 to accommodate a major new client. We are
leveraging our experience from the construction of the Brampton facility for the development of our new
220,000 square foot facility in Mississauga, Ontario.
National Demographics and Healthcare Spending
We believe that we are strategically positioned to directly benefit from the strong growth expected in the
Canadian healthcare sector, which is driven by a number of favourable trends including an aging population,
increased life expectancy and increasing healthcare spending.
Regulatory Environment
In order to maintain the safety, quality and efficacy of healthcare products, government regulations have
been introduced to set out rules relating to, among other things, the packaging, warehousing, distribution,
transportation and temperature monitoring of such products. The pace and complexity of such regulations
has increased in recent years, including through the introduction of, and revisions to, many Health Canada
guidelines, such as Health Canada’s GUI-0069 - Guidelines for Environmental Control of Drugs During
Storage and Transportation (“GUI-0069”), among others. Recognizing the ever-changing regulatory
demands on the healthcare sector, we take a proactive approach to stay aligned with regulatory protocols,
provide environments that are compliant with good manufacturing practices and offer our clients’ real-time
monitoring and reporting. By outsourcing their logistics and transportation needs to specialists, our clients
can focus on their core business.
Competition
We believe that we offer a unique set of services in the marketplace and stand apart from other outsourced
healthcare service providers and traditional logistics and transportation companies. In particular, we believe
our differentiated capabilities, including our temperature management expertise, together with our coast-
to-coast distribution network and multiple service offerings uniquely positions us within our industry and
sets us apart from companies specializing in global integration and supply chain management, national non-
temperature managed solutions, regional temperature managed solutions as well as niche service providers
and insourced transportation services. Notwithstanding the foregoing, we do compete with FedEx,
Purolator, UPS Supply Chain Solutions, Kuehne + Nagel and Lynden Logistics in our delivery of 3PL
services. We also compete with certain regional transportation providers, such as Williams Pharmalogistics
in Quebec and Rogue Transportation Services Inc. in Ontario, as well as Skelton Trucking, primarily in
respect of 2°C to 8°C shipments.
Management & Employees
Our employee culture is one of our fundamental strengths and a strategic priority. Our employees are
passionate about our business and are dedicated to creating and improving solutions for our clients. We
empower our employees through training and professional development programs as well as strong open
lines of communication and encourage our employees to suggest ways in which we can improve our
operations. As our business has grown we have maintained a close connection to our employee base. We
recognize and celebrate our very best employees who act as leaders within our employee team and promote
movement within our organization in an effort to retain and encourage our top talent. As a result of these
- 7 -
efforts, we believe we have good relationships with our employees across our operating segments, none of
whom are subject to collective bargaining agreements.
Cost Escalation
In order to provide the services that we offer, we incur various operating costs. These costs include amongst
others, labour, rent, fuel, equipment, and insurance. We are susceptible to increases in the price of these
items, many of which can fluctuate, often due to factors beyond our control, such as regional and global
supply and demand dynamics, political events, terrorist activities, the strength of the Canadian dollar
relative to other currencies, and natural disasters.
To mitigate the risk of cost escalation, we focus on operational excellence, synergies between our product
lines and cost controls. We rely on, among other things, long-term planning, budgeting processes, and
internal benchmarking to achieve our profitability targets. Additionally, we mitigate the risk of inflation by
utilizing leases to fund our network of facilities, vehicles and logistics equipment and by using third party
service providers. We also mitigate our exposure to rising fuel costs through the implementation of fuel
surcharge programs, which pass the majority of cost increases to our clients. In addition, we have
implemented a number of policies that focus on asset efficiency, including fuel economy, asset utilization,
proper repairs and maintenance of equipment, and measured equipment lease renewals. Many of our
contracts include cost of living indexes that provide for annual price adjustments which further protect us
from the risks of escalating costs.
Acquisitions
We selectively evaluate strategically compelling acquisition opportunities that leverage or expand our
differentiated capabilities. In pursuing potential acquisition candidates, we will assess several criteria to
expand our domestic platform, including: (i) complementary tuck-ins; and (ii) entry or expansion into
growth verticals, new verticals and new service offerings, and will assess opportunities for expansion into
the U.S. or international markets through an existing platform that aligns with our core capabilities and
existing service offering.
Financial and Operational Highlights
We refer the reader to the section entitled “How We Assess the Performance of Our Business” of this
MD&A for the definition of the items discussed below and, when applicable, to the section entitled
“Reconciliation of Non-IFRS Measures” for quantitative reconciliations of net income and comprehensive
income to EBITDA.
Q4 2019 Compared to Q4 2018
Select highlights include the following:
Revenue increased 6.3% to $76.6 million, compared to $72.1 Q4 2018;
Operating income increased 31.4% to $11.3 million, compared to $8.6 million in Q4 2018;
Net income and comprehensive income increased 19.5% to $7.1 million, compared to $5.9 million
in Q4 2018;
EBITDA increased 19.4% to $17.7 million, compared to $14.9 million in Q4 2018;
EBITDA margin increased to 23.1% from 20.6% in Q4 2018;
- 8 -
We completed the construction of our new Calgary facilities, expanding our logistics and
distribution footprint by 23,000 square feet and increasing capacity in our specialty transportation
segment;
We secured a lease on a new 220,000 square-foot facility (commencing July 1, 2020) in the GTA
to service a major new client and to add capacity for future growth; and
We successfully completed our $172.5 million IPO and commenced trading on the TSX.
Fiscal 2019 Compared to Fiscal 2018
Select highlights include the following:
Revenue increased 4.7% to $290.0 million, compared to $277.0 million in Fiscal 2018;
Operating income increased 10.1% to $45.0 million, compared to $40.9 million in Fiscal 2018;
Net income and comprehensive income increased to $30.3 million, from $28.2 million in Fiscal
2018;
EBITDA increased 9.6% to $70.6 million, compared to $64.4 million in Fiscal 2018; and
EBITDA margin increased to 24.3% from 23.2% in Fiscal 2018.
How We Assess the Performance of Our Business
We have historically operated and managed our healthcare logistics and specialized transportation operating
segments as separate businesses with separate management teams. Our healthcare logistics segment has
operated under the brand name Accuristix and our specialized transportation segment has operated under
the brand name ATS Healthcare. Following our IPO, both Accuristix and ATS Healthcare have continued
to operate autonomously, each having its own management. Over time, as we grow, our operating segments
may change. If this occurs, we will reflect the change in our reporting practices.
Both of our operating segments conduct their businesses in a manner that limits capital investments,
preferring to lease facilities and certain equipment rather than allocating significant cash flows to capital
expenditures. We believe our business model provides us with greater flexibility and lower risks, creating
cost savings as compared to more capital expenditure intensive models. Accordingly, lease costs comprise
a significant component of our expenses. Under IFRS 16, leases have been capitalized, resulting in
depreciation and interest expense rather than direct operating expenses, as would have been seen prior to
the adoption of IFRS 16. We believe that the cash flows associated with our lease payments are a relevant
metric in evaluating the performance of our business.
Revenue
We generate revenue from the provision of supply chain solutions to the Canadian healthcare sector. Across
our logistics and transportation operating segments, we generate revenue across five principal product lines:
logistics and distribution, packaging solutions, air freight forwarding, ground transportation, and dedicated
and last mile delivery.
Our healthcare logistics segment, which offers services under our Accuristix brand, generates revenue from
the provision of logistics and distribution services and packaging solutions to our clients. Services are
typically provided under master service agreements with terms that range from three to five years in length.
Our logistics contracts typically include a single performance obligation that is satisfied over time as clients
simultaneously receive and consume the benefits of our services. For this performance obligation, we
recognize revenue at the invoiced amount since this amount corresponds directly to our performance and
the value to the client. In some cases, our agreements include other performance obligations related to
- 9 -
managing transportation and other client services which are included in the logistics and distribution
product. These services are typically priced at their stand-alone selling prices and are recognized over time
on a proportionate and straight-line basis as the client simultaneously receives and consumes the benefits
of our services. Intersegment revenue generated by Credo Systems Canada Inc. from the sale of thermal
packaging containers to ATS Healthcare, as well as intra-segment revenue between Accuristix and Nova
Pack Ltd. (“Nova Pack”) is eliminated on combination.
Our specialized transportation segment, which offers services under our ATS Healthcare brand, generates
revenue from the provision of specialized temperature-controlled, as well as non-temperature controlled,
ground transportation, air freight forwarding and dedicated and last mile transportation services to our
clients. Certain additional services are provided to clients where requested as part of their transportation
contracts, such as chain of custody and other incidental services. Transportation revenue is recognized
proportionally as a shipment moves from origin to destination and the related costs are recognized as
incurred. Performance obligations are short-term, with transit typically taking less than one week.
Generally, clients are billed upon shipment of the freight, and remit payment according to approved
payment terms. Intersegment revenue generated by ATS Healthcare from the provision of transportation
services to Accuristix, on behalf of its logistics clients, is eliminated on combination.
As is customary in our industry, most of our client contracts and transportation pricing terms include fuel-
surcharge revenue programs or cost recovery mechanisms to mitigate the effect of fuel price increases over
base amounts established in the contract. However, these fuel surcharge mechanisms may not capture the
entire amount of changes in fuel prices, and there is also a lag between the payment for fuel and collection
of surcharge revenue. Decreases in fuel prices reduce the cost of transportation and services, and will
accordingly reduce our revenues and may reduce margins for certain product lines.
Cost of Transportation and Services
Our cost of transportation and services expense includes the cost of providing or procuring freight
transportation to our clients. The cost of transportation and services for our specialized transportation
segment includes linehaul costs to connect our national network; pick-up and delivery costs paid to brokers,
agents, and our drivers; fuel, toll fees and maintenance costs; and inbound and outbound handling costs
which are largely comprised of hourly paid dock labour. The cost of transportation and services for our
healthcare logistics segment includes purchased transportation expense, including fuel surcharges, sourced
from carriers. ATS Healthcare is the largest provider of transportation services to Accuristix. Intersegment
purchased transportation expense is eliminated on combination.
Direct Operating Expenses
Direct operating expenses are both fixed and variable and consist of operating costs related to our facilities
(including our distribution centres, branches and the cross-docks that we operate from). Direct operating
expenses consist mainly of personnel costs and facility and equipment expenses such as property taxes,
utilities, equipment maintenance and repair, costs of materials and supplies, security and insurance
expenses. We note that under IFRS 16 the costs associated with our leases are not recognized in our direct
operating expenses.
Selling, General and Administrative Expenses
Selling, General and Administrative Expenses (“SG&A”) primarily consist of the cost of salaries and
benefits for executive and certain administration functions, including information technology, sales and
client service, finance and accounting, professional fees, facility costs, legal costs and other expenses
- 10 -
related to the corporate infrastructure required to support our business. We expect our SG&A to increase
as we incur additional legal, accounting, insurance and other expenses associated with being a public
company.
Depreciation & Amortization
Depreciation and amortization charges comprise non-cash charges expensed on the statement of income
and comprehensive income to spread the purchase price of assets over their useful lives. Within both of our
operating segments, we prefer to lease facilities and certain equipment rather than allocating significant
cash flows to capital expenditures. We believe this approach provides us with greater flexibility and lower
risks and results in cost savings as compared to capital expenditure intensive models. Accordingly, lease
costs comprise a significant component of our expenses. Under IFRS 16, leases have been capitalized,
resulting in depreciation and interest expense rather than direct operating expense.
Operating Income
Operating Income measures the amount of profit derived from our operations after deducting operating
expense such as cost of transportation and services, direct operating expense, SG&A, and depreciation and
amortization. We do not typically measure “cost of sales or gross profit” as we are a service business.
Other Income
Other income comprises income that does not arise from the Company’s main business, such as exchange
gains (losses) and gains resulting from the sale of property, plant and equipment and certain other
insignificant sources.
Interest Income
Interest income comprises interest earned on cash and cash equivalents together with interest earned on
certain amounts due from related parties.
Interest Expense
Interest expense comprises interest charged to the statement of income and comprehensive income
primarily in connection with leased facilities and equipment under IFRS 16. Interest and bank charges and
interest paid for amounts due to related parties are also included. In connection with our IPO, we entered
into the Credit Facilities. Accordingly, the Company has begun to incur interest expense on the Credit
Facilities since December 11, 2019.
Income Tax Expense
Income tax expense comprises the amount that we have recognized in the accounting period related to our
taxable income. Our effective tax rate is generally close to the statutory rate, but certain differences between
income for tax and accounting income are recognized in the deferred income tax provision.
Non-IFRS Measures
EBITDA
We define EBITDA as net income and comprehensive income for the period before: (i) income tax
(recovery) expense; (ii) interest income; (iii) interest expense; and (iv) depreciation and amortization.
- 11 -
We believe EBITDA is a useful measure to assess our financial performance because it provides a more
relevant picture of operating results by excluding the effects of expenses that are not reflective of our
underlying business performance.
EBITDA Margin
We define EBITDA Margin as EBITDA divided by revenue. EBITDA Margin represents a measure of our
profitability expressed as a percentage of revenue.
We believe EBITDA Margin is a useful measure to assess our financial performance because it helps
quantify our ability to convert revenues generated from clients into EBITDA.
EBITDA less Leases and CAPEX
We define EBITDA less Leases and CAPEX as EBITDA less cash payments for leases and capital
expenditures.
We believe EBITDA less Leases and CAPEX is a useful measure to assess our financial performance
because it provides a measure of our operating earnings after reflecting the cash outflows associated with
our leases and capital expenditures, including spending on leases, property plant and equipment and
intangibles such as software, but before items which we view as non-operational such as depreciation,
amortization, interest expense and taxes. We believe this is a useful measure when comparing our business
to others in the sector.
EBITDA less Leases and CAPEX Conversion
We define EBITDA less Leases and CAPEX Conversion as EBITDA less Leases and CAPEX divided by
EBITDA.
We believe EBITDA less Leases and CAPEX Conversion is a useful measure to assess our financial
performance because it demonstrates our ability to generate EBITDA less Leases and CAPEX in relation
to our EBITDA. We believe this is a useful measure when comparing our business to others in the sector.
EBITDA less Leases and CAPEX Margin
We define EBITDA less Leases and CAPEX Margin as EBITDA less Leases and CAPEX divided by
revenue.
We believe EBITDA less Leases and CAPEX Margin is a useful measure to assess our financial
performance because it allows us to evaluate our ability to generate EBITDA less Leases and CAPEX in
relation to the revenues we earn from our clients. We believe this is a useful measure when comparing our
business to others in the sector.
- 12 -
Selected Consolidated Financial Information
The following table summarizes our results of operations for the periods indicated. The selected
consolidated financial information for Q4 2019, Q4 2018, Fiscal 2019, Fiscal 2018 and Fiscal 2017 has
been derived from our consolidated financial statements and related notes.
($CAD 000s)
Revenue
Logistics & Distribution
Packaging
Healthcare Logistics Segment
Ground Transportation
Air Freight Forwarding
Dedicated and Last Mile Delivery
Intersegment Eliminations
Specialized Transportation Segment
Total revenue
Operating Expenses
Cost of transportation and services
Direct operating expense
Selling, general and administrative
expenses
Depreciation & amortization
Three Months Ended
December 31,
2019
2018
22,664
4,892
27,556
45,685
5,236
4,828
(6,704)
49,045
76,601
32,621
18,586
7,543
6,503
65,253
21,046
5,456
26,502
42,391
5,336
3,771
(5,905)
45,593
72,095
31,392
19,236
6,672
6,160
63,460
Year Ended
December 31,
2018
85,125
21,305
106,430
160,489
19,332
13,899
(23,140)
170,580
277,010
116,780
74,190
21,683
23,491
236,144
2019
88,311
21,307
109,618
169,040
19,656
16,689
(25,015)
180,370
289,988
121,405
74,792
23,092
25,706
244,995
2017
80,895
15,161
96,056
143,919
17,696
12,327
(18,968)
173,942
251,030
105,150
67,864
20,394
23,629
217,037
Operating income
11,348
8,635
44,993
40,866
33,993
Other (expense) income
Interest income
Interest expense
Income tax expense
Net income and comprehensive
income
Net income and comprehensive
income attributable to
Shareholders of the Company
Non-controlling interests
Earnings per share(1) – basic
Earnings per share(1) – diluted
Select financial metrics
EBITDA
EBITDA Margin
EBITDA less Leases and CAPEX
EBITDA less Leases and CAPEX
Conversion
EBITDA less Leases and CAPEX
Margin
(122)
276
(980)
(3,447)
55
278
(800)
(2,249)
(145)
1,004
(3,503)
(12,004)
19
879
(3,048)
(10,531)
439
404
(3,135)
(8,517)
7,075
5,919
30,345
28,185
23,184
7,075
-
$0.19
$0.19
17,729
23.1%
8,601
48.5%
11.2%
5,720
199
N/A
N/A
14,850
20.6%
8,302
55.9%
11.5%
29,773
572
$0.79
$0.79
70,554
24.3%
42,326
60.0%
14.6%
26,723
1,462
N/A
N/A
64,376
23.2%
42,135
65.5%
15.2%
21,678
1,506
N/A
N/A
58,061
23.1%
36,379
62.7%
14.5%
(1) Earnings per share data is not presented for 2018 as AHG was not incorporated until November 12, 2019. Earnings per share is in respect of
profit from continuing operations attributable to shareholders of the Company
- 13 -
Consolidated Balance Sheets
($CAD 000s)
Select financial position data
Total assets
Total non-current liabilities
Consolidated Statements of Changes in Equity
2019
As At December 31,
2018
2017
212,995
94,795
276,577
61,772
267,962
60,726
($CAD 000s)
Select financial data
Distributions to related parties
Dividends paid to non-controlling
interest
Three Months Ended
December 31,
2019
2018
Year Ended
December 31,
2018
2019
(112,016)
(25,850)
(112,016)
(25,850)
-
(150)
-
(150)
2017
(700)
(300)
Reconciliation of Non-IFRS Measures
The following table provides a reconciliation of net income and comprehensive income to EBITDA and to
EBITDA less Leases and CAPEX for Q4 2019, Q4 2018, Fiscal 2019 and Fiscal 2018:
($CAD 000s)
Net income and comprehensive
income
Income tax expense
Interest income
Interest expense
Depreciation & amortization
EBITDA
Capital expenditures
Lease payments
EBITDA less Leases and CAPEX
Results of Operations
Three Months Ended
December 31,
2019
2018
7,075
3,447
(276)
980
6,503
17,729
(3,286)
(5,842)
8,601
5,919
2,249
(278)
800
6,160
14,850
(1,310)
(5,238)
8,302
Year Ended
December 31,
2018
28,185
10,531
(879)
3,048
23,491
64,376
(2,508)
(19,733)
42,135
2019
30,345
12,004
(1,004)
3,503
25,706
70,554
(5,935)
(22,293)
42,326
2017
23,184
8,517
(404)
3,135
23,629
58,061
(2,419)
(19,263)
36,379
Three and Months Ended December 31, 2019 Compared with 2018
The following section provides an overview of our financial performance for Q4 2019 and Q4 2018.
Although our business continued to operate in its normal course throughout Q4 2019, a significant event
occurred with the completion of our IPO on December 11, 2019. In connection with our IPO, certain
expenses, such as transaction costs and the cost of share-based compensation arrangements for directors,
officers, and certain key management employees were recognized in Q4 2019. The impact of these costs is
discussed in the SG&A section below.
Revenue
Revenue for Q4 2019 increased by 6.3% to $76.6 million compared with Q4 2018. Revenue growth was
led by continued volume growth in ground transportation and by new contracts in logistics and distribution
and dedicated and last mile delivery products, resulting in approximately $4.5 million of incremental
revenue.
Healthcare Logistics Segment
- 14 -
Revenue in our healthcare logistics segment increased by 4.0% for Q4 2019, or approximately $1.1 million,
to $27.6 million, compared with Q4 2018. Revenue growth in this segment was primarily driven by the
factors set out below.
Logistics & Distribution
Logistics and distribution revenue for Q4 2019 increased by 7.7%, or approximately $1.6 million, to $22.6
million, compared with Q4 2018. We did not obtain any significant new clients during the quarter, but
revenue was bolstered by higher handling and transportation revenues driven by higher volumes from
existing clients.
Packaging
Packaging revenue for Q4 2019 decreased by 10.3%, or approximately $0.6 million, to $4.9 million,
compared with Q4 2018. Q4 2019 was impacted by the decision of our largest packaging client to defer
certain projects until the first quarter of 2020. Accordingly, we expect above average growth for the
packaging product in January and February of 2020.
Specialized Transportation Segment
Revenue in our specialized transportation segment for Q4 2019 increased by 7.7%, or approximately $3.5
million to $49.0 million, compared with Q4 2018. Revenue growth in this segment was primarily driven by
the factors set out below.
Air Freight Forwarding
Air freight forwarding revenue for Q4 2019 decreased by 1.9% or approximately $0.1 million to $5.2
million, compared with Q4 2018. Revenue growth for air freight forwarding has been slower than other
products as clients generally try to minimize expedited shipping by air due to its relatively high cost as
compared to ground transportation.
Ground Transportation
Ground transportation revenue for Q4 2019 increased by 7.8%, or approximately $3.3 million, to $45.7
million, compared with Q4 2018. Revenue was primarily impacted by increased volume from our existing
client base.
Dedicated and Last Mile Delivery
Dedicated and last mile delivery revenue for Q4 2019 increased by 28.0%, or approximately $1.1 million,
to $4.8 million, compared with Q4 2018. Revenue was primarily impacted by expanded routes for existing
clients. Dedicated and last mile delivery growth is expected to continue as Health Canada expands its
enforcement of GUI-0069 in connection with temperature-controlled transportation.
Cost of Transportation and Services
Cost of transportation and services for Q4 2019 was $32.6 million, or 42.6% of revenue, compared with
$31.4 million, or 43.5% of revenue, for Q4 2018. The cost of transportation and services operating ratios
- 15 -
for the three months ended both periods are in line with prior years with no major fluctuations in costs
versus revenue.
Direct Operating Expenses
Direct operating expenses for Q4 2019 were $18.6 million, or 24.3% of revenue, compared with $19.2
million, or 26.7% of revenue, for Q4 2018. The year-over-year operating ratios for direct operating expenses
in relation to revenue are consistent with prior years with no major factors influencing variances. In October
2019 we expanded our ATS branch capacity in Calgary and relocated our Accuristix distribution centre to
a new and larger facility in Calgary. Accordingly, we experienced increases in direct operating expenses in
November and December, 2019 in relation to both Calgary expansions as we invested to support future
growth. These additional costs were offset by improved efficiencies and the recovery of costs in connection
with our Calgary relocation from logistics and distribution clients.
Selling, General and Administrative Expenses
SG&A for Q4 2019 was $7.5 million, or 9.8% of revenue, compared with $6.7 million, or 9.3% of revenue,
for Q4 2018. SG&A expenses for Q4 2019 include IPO transaction costs of approximately $1.0 million, or
1.2% of revenue, which are incremental to the historical SG&A expense reflected in our operating income.
A further $1.4 million, or 1.8% of revenue, was expensed in connection with the Company’s share-based
payment arrangements. These increased costs in Q4 2019 were partially offset by a special one-time
employee compensation cost in the specialized transportation segment in Q4 2018. The Company expects
approximately $2.0 million of incremental annual costs to be incurred as a result of being a public company
in 2020 and each year thereafter as compared to its prior costs as a private company.
Depreciation and Amortization
Depreciation and amortization for Q4 2019 was $6.5 million compared with $6.2 million for Q4 2018. The
increase in depreciation and amortization of $0.3 million for Q4 2019 represents a 5.6% year-on-year
increase and is attributable to leases for new right of use logistics and transportation equipment to support
growth in the specialized transportation segment. Our new leased facilities in Calgary came online during
Q4 2019 in connection with our expansion to support future growth, which accounts for the majority of the
year-on-year increase.
Other Income/Expense
Other expense for Q4 2019 was $0.1 million compared with other income of $0.1 million for Q4 2018.
These amounts are immaterial to the overall performance of the Company for these quarters.
Interest Income
Interest income for Q4 2019 was $0.3 million compared with $0.3 million for Q4 2018.
Interest Expense
Interest expense for Q4 2019 was $1.0 million compared with $0.8 million for Q4 2018. Interest expense
related to leased facilities and equipment comprises the significant majority of interest expense; however,
$0.1 million of interest expense was incurred in connection with the Credit Facilities which were entered
into in connection with the IPO. The Company expects to continue to hold debt under the Term Facility,
which does not have any repayment schedule except as a single repayment at the end of the term, and will
incur interest expense on the Term Facility for the duration of the term (four years).
Income Tax Expense
- 16 -
Income tax expense for Q4 2019 was $3.4 million compared with $2.2 million for Q4 2018. Income tax
expense for Q4 2019 is higher than what would be expected at the statutory rate because deferred tax assets
have not been recognized in respect of tax losses related to IPO transaction costs. In addition, deductible
temporary differences, comprising IPO transaction costs which have been charged directly to equity, have
not yet been recognized. The Company is evaluating alternatives under which sufficient future taxable profit
will be available against which the Company can use the benefits therefrom.
Operating Income and Net Income and Comprehensive Income
Operating income for Q4 2019 was $11.3 million compared with $8.6 million for Q4 2018, representing an
increase of $2.7 million, or 31.4%.
Net Income and comprehensive income for Q4 2019 increased by 19.5%, or $1.2 million, to $7.1 million,
from $5.9 million for Q4 2018. Operating income and net income and comprehensive income increased
over the prior year due to the factors discussed above.
EBITDA
EBITDA for Q4 2019 increased by 19.4%, to $17.7 million, from $14.9 million for Q4 2018. EBITDA
increased over the year due to the factors discussed above.
EBITDA Margin
EBITDA Margin for Q4 2019 improved to 23.1% from 20.6% for Q4 2018. Operating leverage was created
for Q4 2019 versus the prior year as increases in our two most significant operating costs (cost of
transportation and services and direct operating expenses) were lower than the increases in revenue growth.
Fiscal 2019 Compared With Fiscal 2018
The following section provides an overview of our financial performance during Fiscal 2019 compared
with Fiscal 2018.
Revenue
Revenue for Fiscal 2019 increased by 4.7%, or approximately $13.0 million, to $290.0 million, compared
with Fiscal 2018. Revenue was impacted by a combination of volume growth and price increases in ground
transportation, new contracts in logistics and distribution and higher project volumes in packaging. All
product lines, except packaging, demonstrated year-on-year growth for 2019.
Healthcare Logistics Segment
Revenue in our healthcare logistics segment for Fiscal 2018 increased by 3.0%, or approximately $3.2
million, to $109.6 million, compared with Fiscal 2018. Revenue growth in this segment was primarily
driven by the factors set out below.
Logistics & Distribution
Logistics and distribution revenue for Fiscal 2019 increased by 3.7%, or approximately $3.2 million, to
$88.3 million, compared with Fiscal 2018. Revenue growth was primarily driven by the full year impact of
new clients on-boarded during 2018 and partial contribution of new clients implemented during 2019.
Packaging
- 17 -
Packaging revenue for Fiscal 2019 was flat at approximately $21.3 million, compared with Fiscal 2018.
Revenue was primarily impacted by a deferral of fourth quarter projects by Nova Pack’s largest client to
the first quarter of 2020. The Company expects stronger than average quarterly volumes for the first quarter
of 2020 as a result.
Specialized Transportation Segment
Revenue in our specialized transportation segment for Fiscal 2019 increased by 5.7%, or approximately
$9.8 million, to $180.4 million, compared with Fiscal 2018. Revenue growth in this segment was primarily
driven by the factors set out below.
Air Freight Forwarding
Air freight forwarding revenue for Fiscal 2019 increased by 1.7%, or approximately $0.3 million, to $19.7
million, compared with Fiscal 2018. Revenue was primarily impacted by 3% lower total weight shipped
offset by price increases.
Ground Transportation
Ground transportation revenue for Fiscal 2019 increased by 5.3%, or approximately $8.6 million, to $169.0
million, compared with Fiscal 2018. Revenue was primarily impacted by continued strong demand for
temperature controlled (ambient 15°C to 25°C) transportation services and revenue management activity
resulting in price increases. Approximately half of the revenue increase was due to increased year-on-year
volume from our existing client base, with the remainder attributed to price increases.
Dedicated and Last Mile Delivery
Dedicated and last mile delivery revenue for Fiscal 2019 increased by 20.1%, or approximately $2.8
million, to $16.7 million, compared with Fiscal 2018. Year-on-year growth in revenue was driven by
expansion of routes from existing clients, as certain wholesale and veterinary distributors deployed
temperature-controlled transportation more broadly within Canada to address increased Health Canada
enforcement of GUI-0069.
Cost of Transportation and Services
Cost of transportation and services for Fiscal 2019 was $121.4 million, or 41.9% of revenue, compared
with $116.8 million, or 42.2% of revenue, for Fiscal 2018. The year-over-year improvement as a percentage
of revenue was primarily driven by a stabilization of costs for employee drivers and outsourced carriers as
the Company experienced the effects of a general shortage of drivers in Fiscal 2018.
Direct Operating Expenses
Direct operating expenses for Fiscal 2019 were $74.8 million, or 25.8% of revenue, compared with $74.2
million, or 26.8% of revenue, for Fiscal 2018. The slight year-over-year improvement as a percentage of
revenue was primarily driven by improved efficiency through productivity gains and growth in revenue
while leveraging our available facility capacity, in addition to improved utilization of our branch facilities.
Selling, General and Administrative Expenses
- 18 -
SG&A for Fiscal 2019 was $23.1 million, or 8.0% of revenue, compared with $21.7 million, or 7.8% of
revenue, for Fiscal 2018. The year-over-year decline as a percentage of revenue was primarily driven by
expenses attributable to the IPO. The Company proactively manages its overhead costs and attempts to
limit increases in SG&A costs, including employee costs, to activities that will drive additional revenue.
Depreciation and Amortization
Depreciation and amortization for Fiscal 2019 was $25.7 million, compared with $23.5 million for Fiscal
2018. The increase is attributed to continued investment in facilities and equipment to support the
Company’s growth.
Other Income/Expense
Other expense for Fiscal 2019 was $(0.1) million, compared with other income of $0.0 million for Fiscal
2018, due primarily to losses on the disposal of equipment realized in Fiscal 2019.
Interest Income
Interest income for Fiscal 2019 was $1.0 million, compared with $0.9 million for Fiscal 2018, due to
increased cash and cash equivalents balances throughout the year up to the date of the IPO. The Company’s
capital structure has changed in connection with the IPO. Moving forward, interest income is expected to
be negligible.
Interest Expense
Interest expense for Fiscal 2019 increased to $3.5 million, compared with $3.0 million for Fiscal 2018 in
connection with increases in leased facilities and equipment to support growth in our business. Interest
expense related to leased facilities and equipment comprises the significant majority of interest expense,
with interest expense in connection with the Company’s Credit Facilities amounting to $0.1 million for
Fiscal 2019 (Fiscal 2018 - $nil).
Income Tax Expense
Income tax expense for Fiscal 2019 was $12.0 million, compared with $10.5 million for Fiscal 2018.
Income tax expense for Fiscal 2019 is higher than what would be expected at the statutory rate because
deferred tax assets have not been recognized in respect of tax losses related to IPO transaction costs. In
addition, deductible temporary differences, comprising IPO transaction costs which have been charged
directly to equity, have not yet been recognized. The Company is evaluating alternatives under which
sufficient future taxable profit will be available against which the Company can use the benefits therefrom.
Operating Income and Net Income and Comprehensive Income
Operating income for Fiscal 2019 was $45.0 million, compared with $40.9 million for Fiscal 2018,
comprising an increase of $4.1 million or 10.1%. Net Income and comprehensive income for Fiscal 2019
increased by 7.7%, or $2.1 million, to $30.3 million from $28.2 million in Fiscal 2018. Operating income
and net income and comprehensive income increased over the prior year due to the factors discussed above.
EBITDA
- 19 -
EBITDA for Fiscal 2019 increased by 9.6%, or $6.2 million, to $70.6 million from $64.4 million in Fiscal
2018. EBITDA increased over the year due to the factors discussed above.
EBITDA Margin
EBITDA Margin for Fiscal 2019 improved slightly to 24.3% from 23.2% in Fiscal 2018. Improvements in
cost of transportation and services and direct operating expenses more than offset the deterioration of the
SG&A expenses (including the one-time transaction costs associated with the IPO).
Summary of Quarterly Results
While there is no significant seasonality to our business, our results are impacted by our clients’ storage
and shipping activities throughout the year as well as the timing of new client implementations or exits.
The table below sets out our results for each of the eight most recently completed quarters:
($CAD 000s) except per share data
Total revenue
Operating income
Net income and comprehensive income
Net income and comprehensive income
attributed to shareholders of the
Company
EBITDA
Earnings per share – basic(1)
Earnings per share - diluted(1)
4Q-19
76,601
11,348
7,075
3Q-19
71,040
11,265
7,766
2Q-19
72,004
11,372
7,958
1Q-19
70,343
11,008
7,546
4Q-18
72,095
8,635
5,919
3Q-18
66,222
9,680
6,561
2Q-18
67,984
11,391
7,892
1Q-18
70,709
11,160
7,813
7,075
17,729
$0.19
$0.19
7,766
17,857
N/A
N/A
7,644
17,680
N/A
N/A
7,288
17,288
N/A
N/A
5,720
14,850
N/A
N/A
6,293
15,587
N/A
N/A
7,324
17,152
N/A
N/A
7,386
16,787
N/A
N/A
(1) Earnings per share data is not presented for 2018 or the first three quarters of 2019 as AHG was not incorporated until November 12, 2019.
Earnings per share is in respect of profit from continuing operations attributable to shareholders of the Company.
Revenue has trended upwards through the past eight quarters with the final quarter in 2019 reflecting both
strong shipping volumes from our clients as well as the impact of price increases which were contractually
implemented in the specialized transportation segment.
Operating income, net income and comprehensive income, and EBITDA for Q4 2018 reflect a one-time
special bonus paid to certain executives of $1.6 million. Operating income, net income and comprehensive
income, and EBITDA for Q4 2019 reflect IPO transaction costs and share-based compensation expenses
totaling $2.4 million which are incremental to the historical performance of the Company.
Liquidity & Capital Resources
Overview
Our principal uses of funds are for operating expenses, taxes, interest, capital expenditures, lease payments,
and distributions to related parties. We believe that cash generated from our operations, together with
amounts available under the Credit Facilities will be sufficient to meet our future operating expenses, taxes,
interest, capital expenditures, lease payments and any further distributions to related parties. In addition,
we believe that our EBITDA less Leases and CAPEX provides us with significant financial flexibility to
service our debt and to pursue our future growth strategies. However, our ability to fund operating expenses,
taxes, interest, capital expenditures, future lease payments, and distributions to related parties will depend
on, among other things, our future operating performance, which will be affected by general economic,
- 20 -
financial and other factors, including factors beyond our control. See “Accounting Classifications and Fair
Values”, “Summary of Factors Affecting Performance” and “Risk Factors” in this MD&A. We review
potential acquisitions and investment opportunities in the normal course of our business and may make
select acquisitions and investments to implement our growth strategy when suitable opportunities arise.
Working Capital
The following table presents our working capital position as at December 31, 2019 and 2018:
($CAD 000s)
Cash and cash equivalents
Accounts receivable
Inventories
Prepaid expenses and other
Due from related parties
Due from Employee Trust
Revolving Credit Facility
Accounts payable and accrued liabilities
Current portion of lease liabilities
Income taxes payable
Working Capital
As At December 31,
2018
2019
18,712
51,060
1,071
2,307
239
13,875
(3,929)
(24,942)
(19,129)
(8,695)
30,569
53,657
48,430
1,366
1,448
54,957
-
-
(27,096)
(17,940)
(41)
114,781
As at December 31, 2019 we had $30.6 million of working capital compared to $114.8 million of working
capital as at December 31, 2018. The $84.2 million decrease in working capital is attributed to the Pre-IPO
Reorganization. We made net distributions to related parties and paid dividends to non-controlling interests
of $112.0 million in Fiscal 2019 (Fiscal 2018 - $26.0 million) which reduced our cash and total working
capital balances. The year-over-year decrease in working capital was partially offset by a loan made to the
Employee Trust in connection with the closing of our IPO.
Credit Facilities
We entered into the Credit Facilities upon closing of our IPO, comprised of the Revolving Credit Facility
and the Term Facility. As at December 31, 2019, the aggregate amount outstanding under the Credit
Facilities was approximately $3.9 million under the Revolving Credit Facility and $25 million under the
Term Facility). The Credit Facilities will mature and be due and payable on December 11, 2023.
The Revolving Credit Facility is available to be drawn in Canadian dollars by way of prime rate loans,
bankers’ acceptances and letters of credit, and in U.S. dollars by way of base rate loans, LIBOR based loans
and letters of credit, in each case, plus the applicable margin in effect from time to time. The Term Facility
was drawn in a single Canadian dollar advance on closing of the IPO by way of prime rate loans and
bankers’ acceptances.
In order to support future potential growth through acquisitions, the Credit Facilities also include an
accordion feature to allow us to increase the commitment under one or both of the Credit Facilities in an
aggregate principal amount of up to $100.0 million, such that any amounts drawn under the accordion
feature would be in addition to the amounts ordinarily available, subject to the agreement of participating
lenders and provided that the Company is not, or would not, be in default under the Credit Facilities or in
non-compliance with any financial covenants and an event of default does not or would not exist, after
giving effect thereto and provided that all representations and warranties are true and correct immediately
- 21 -
prior to, and after giving effect to, such increase. As of the date of this MD&A, this accordion feature
remains uncommitted.
Capital Expenditures
Capital expenditures for Q4 2019 were $3.3 million (Q4 2018 - $1.3 million) and in Fiscal 2019 were $5.9
million (Fiscal 2018 - $2.5 million). Capital expenditures have historically been funded through cash flows
from operations. Management has traditionally divided its capital expenditures into two subcategories,
Capital Expenditures (Maintenance) and Capital Expenditures (Growth), which are further detailed below.
There are no known trends or expected fluctuations in the Company’s capital resources, including expected
changes in the mix and relative cost of these resources.
Capital Expenditures (Maintenance)
Maintenance CAPEX refers to capital expenditures necessary for us to sustain our assets in order to continue
operating in our current form. We generally seek to maintain our facilities and equipment at a level
consistent with the needs of the sector we operate within and ensure that preventative maintenance programs
are in place to achieve the performance expected from our facilities and equipment. Outlays for maintenance
capital expenditures for Q4 2019 were $0.3 million (Q4 2018 - $0.2 million) and in Fiscal 2019 were $1.5
million (Fiscal 2018 - $1.2 million). These capital expenditures have historically been funded through cash
flows from operations.
Capital Expenditures (Growth)
Growth CAPEX comprises expenditures on new assets that are intended to grow our productive capacity.
These capital expenditures are made to acquire or expand leasehold improvements, transportation and
logistics equipment (including pick-up and delivery equipment, warehouse racking, material handling
equipment, warehouse automation equipment and specialized logistics equipment such as coolers or vaults,
among others), furniture and fixtures, computer equipment to support new contracts or additional volume
from new business. Outlays for growth capital expenditures for Q4 2019 were $3.0 million (Q4 2018 - $1.1
million) and in Fiscal 2019 were $4.4 million (Fiscal 2018 - $1.3 million) and can range from $1.0 million
up to $10.0 million in any given year, depending on the underlying expansion need. Growth CAPEX has
also historically been funded through cash flows from operations.
- 22 -
Cash Flows
The following table presents cash flows for Q4 2019, Q4 2018, Fiscal 2019 and Fiscal 2018:
($CAD 000s)
Cash flows
Cash from Operating Activities
Cash used in Investing Activities
Cash used in Financing Activities
Net change in cash
Select cash flow data
Capital expenditures
Lease payments
Three Months Ended
December 31,
Year Ended
December 31,
2019
2018
2019
2018
26,581
(3,397)
(40,665)
(17,481)
14,160
(1,256)
(6,381)
6,523
61,001
(6,165)
(89,781)
(34,945)
52,338
(2,497)
(46,332)
3,509
(3,286)
(5,842)
(1,310)
(5,238)
(5,935)
(22,293)
(2,508)
(19,733)
Select financial metrics
EBITDA less Leases and CAPEX
EBITDA less Leases and CAPEX Conversion
EBITDA less Leases and CAPEX Margin
8,601
48.5%
11.2%
8,302
55.9%
11.5%
42,326
60.0%
14.6%
42,135
65.5%
15.2%
EBITDA less Leases and CAPEX and EBITDA less Leases and CAPEX Conversion
Our EBITDA less Leases and CAPEX, which represents the earnings we generate after cash outflows to
support operations and maintain our capital assets, was $8.6 million for Q4 2019 compared to $8.3 million
for Q4 2018.
Our EBITDA less Leases and CAPEX increased to $42.3 million in Fiscal 2019 from $42.1 million in
Fiscal 2018. The EBITDA less Leases and CAPEX generated in Fiscal 2019 represented a 60.0% EBITDA
less Leases and CAPEX Conversion (Fiscal 2018 – 65.5%), demonstrating our continued ability to finance
our ongoing growth and provide shareholders with the opportunity for dividends. EBITDA less Leases and
CAPEX in Fiscal 2019 versus Fiscal 2018 reflects increased expenditures associated with the opening of
our new facilities in Calgary.
Cash Flow Generated From Operating Activities
Cash flows generated from operating activities for Q4 2019 totaled $26.5 million and versus $14.1 million
for the same period in 2018. The increases in cash flows generated from operating activities relate
principally to normal fluctuations in trade accounts receivable and trade accounts payable balances.
Cash flows generated from operating activities in Fiscal 2019 totaled $61.0 million (Fiscal 2018 – $52.3
million). The increase in cash flow from operations is the result of strong and stable margins fueled by
organic growth, generated from a mix of new clients, increased pricing and increased volumes, across our
five product lines.
Cash Flow (Used In) Investing Activities
Cash flows used in investing activities for Q4 2019 and Fiscal 2019 reflect growth-based capital
expenditures of $3.0 million and $4.4 million respectively, in connection with the expansion to two facilities
in Calgary.
Cash Flow (Used In) Financing Activities
- 23 -
We operate our business by utilizing leases to primarily finance our vehicles and facilities, resulting in
significant lease payments on an annual basis. We paid $22.3 million for leases, including interest expense,
in Fiscal 2019 (Fiscal 2018 - $19.7 million). Further, we made distributions to related parties in Fiscal 2019
of $112.0 million (Fiscal 2018 – 25.8 million) and paid dividends to non-controlling interests in Fiscal 2018
of $0.2 million.
Contractual Obligations
As at December 31, 2019, the Company had the following contractual commitments:
Outstanding letters of guarantee in the amount of $180 (December 31, 2018 – $68).
A lease agreement, entered into by the Company on November 28, 2019, relating to a facility
located at 200 Edgeware Road, Brampton, Ontario for a 7-year lease term commencing on July 1,
2020. Total lease commitments over this term amount to $15,450. In relation to the same facility,
the Company entered into a construction agreement on November 28, 2019 with Orlando
Corporation Inc., as contractor, and Stevron Holdings Limited, as landlord, committing to
construction work of $2,484, of which the landlord has provided $1,200 in cash allowances,
received in January 2020. Construction of the facility is expected to be completed by June 2020.
Commitments relating to the leasing of fleet equipment, ranging from 60 to 84 months, beginning
upon delivery to the Company of the equipment in 2020, for total lease commitments of $2,987.
Credit facilities
As at December 31, 2019, the aggregate amount outstanding under the Credit Facilities was approximately
$3.9 million under the Revolving Credit Facility and $25 million under the Term Facility). The Credit
Facilities will mature and be due and payable on December 11, 2023.
Leases
We lease buildings and equipment in the operation of our healthcare logistics and specialized transportation
business. Building lease terms range from five to ten years, with many leases including optional extension
periods. For Fiscal 2019, building lease liabilities are calculated using our average incremental borrowing
rate of 3.75% (Fiscal 2018 – 3.69%). Equipment lease terms range from one to five years. For Fiscal 2019,
equipment lease liabilities are calculated using our incremental borrowing rate of 4.07% (Fiscal 2018 –
4.66%) for our specialized transportation segment and 3.95% (Fiscal 2018 – 4.37%) for our healthcare
logistics segment.
The following table summarizes our contractual obligations as at December 31, 2019, and 2018 based on
undiscounted cash flows:
($CAD 000s)
Credit Facilities
Lease liabilities
Other obligations
Total contractual obligations
Total
28,484
118,818
34,293
181,595
Less than
1 Year
1-5 Years
More than
5 years
-
23,714
33,637
57,351
28,484
71,654
656
100,794
-
23,450
-
23,450
- 24 -
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements that have or are reasonably expected to have a current or future
material impact on our financial condition, revenues or expenses, results of operations, liquidity, capital
expenditures or capital resources.
Seasonality
There is no significant seasonality to our business.
Financial Instruments
Financial assets
Accounts receivable are initially recognized when they are originated. All other financial assets and
financial liabilities are initially recognized when we become a party to the contractual provisions of the
instrument.
A financial asset (unless it is an account receivable without a significant financing component) or financial
liability is initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL),
transaction costs that are directly attributable to its acquisition or issue. An account receivable without a
significant financing component is initially measured at the transaction price.
Our financial assets are comprised of cash and cash equivalents, accounts receivable, due from related
parties, and long-term deposits. On initial recognition, we classify these financial assets as measured at
amortized cost, when both of the following conditions are met:
•
•
it is held within a business model whose objective is to hold assets to collect contractual cash
flows; and
its contractual terms give rise on specified dates to cash flows that are solely payments of
principal and interest on the principal amount outstanding.
These financial assets are subsequently measured at amortized cost using the effective interest method. The
amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and
impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or
loss.
Impairment of financial assets
Financial assets are assessed for indicators of impairment at the end of each reporting period. Financial
assets are considered to be impaired when there is objective evidence that, as a result of one or more events
that occurred after the initial recognition of the financial asset, the estimated future cash flows of the
investment have been decreased.
For accounts receivable, we apply a simplified approach in calculating expected credit losses (“ECLs”).
Therefore we do not track changes in credit risk, but instead recognize a loss allowance based on lifetime
ECLs at each reporting date. We have established a provision matrix that is based on our historical credit
loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.
- 25 -
When an account receivable is considered uncollectible, it is written off against the allowance account.
Subsequent recoveries of amounts previously written off are offset against the allowance account. Changes
in the carrying amount of the allowance account are recognized in profit or loss.
Financial liabilities
Our financial liabilities are comprised of accounts payable and accrued liabilities, lease liabilities, income
taxes payable and amounts due from related parties. Our financial liabilities are measured at amortized cost
using the effective interest method. Interest expense and foreign exchange gains and losses are recognized
in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss.
Related Party Transactions
Intercompany balances and transactions have been eliminated in our consolidated financial statements.
During the year, we entered into transactions with related parties that were incurred in the normal course
of business. Our policy is to conduct all transactions and settle all balances with related parties on market
terms and conditions. All outstanding balances with these related parties are measured at amortized cost
and are to be settled in cash within two months of the reporting date. None of the balances are secured. No
expense has been recognized in the current year or prior year for bad or doubtful debts in respect of amounts
owed by related parties.
Certain of our operating units provide services to other operating units outside of their reportable segment.
Billings for such services are based on negotiated rates, which approximate fair value, and are reflected as
revenues of the billing segment. These rates are adjusted from time to time based on market conditions.
Such intersegment revenues and expenses are eliminated in our consolidated results. Michael Andlauer, our
Chief Executive Officer, is also our Chief Operating Decision Maker (“CODM”). The CODM regularly
reviews financial information at the operating segment level in order to make decisions about resources to
be allocated to the segments and to assess their performance. Segment results that are reported to the CODM
include items directly attributable to a segment, as well as those that can be allocated on a reasonable basis.
We evaluate performance based on the various financial measures of our two operating segments.
The amounts below are expressed in thousands of Canadian dollars, unless otherwise specified.
Andlauer Management Group Inc.
As of the date hereof, AMG holds all of the Multiple Voting Shares of the Company and 75,000 Subordinate
Voting Shares, representing approximately 67% of the issued and outstanding Shares and 89% of the voting
power attached to all of the Shares. AMG is owned and controlled by Michael Andlauer, our Chief
Executive Officer and a director of the Company.
In connection with the IPO, AHG acquired the AHG Entities from AMG in consideration for the issuance
of: (i) 25,175,000 Multiple Voting Shares, (ii) a non-interest bearing promissory note in the aggregate
principal amount of $186,125 (“Acquisition Note 1”) and (iii) a non-interest bearing convertible promissory
note in the principal amount of $13,875 (“Acquisition Note 2”), which was convertible into 925,000
Subordinate Voting Shares at the option of the holder. Upon closing of our IPO on December 11, 2019, we
used the aggregate net proceeds raised from the IPO, totaling $150,000, together with a draw of $50,000
from our Credit Facilities, to repay Acquisition Note 1, and make a non-interest bearing loan to the
Employee Trust in the principal amount of $13,875 (the “Employee Trust Loan”). On that same date, AMG
converted Acquisition Note 2 into 925,000 Subordinate Voting Shares (which the Employee Trust
subsequently acquired using the proceeds from the Employee Trust Loan), and converted 75,000 of the
- 26 -
Multiple Voting Shares received pursuant to the Purchase Agreement into 75,000 Subordinate Voting
Shares (which it intends to transfer, at least 180 days after closing of the IPO, to select independent owner-
operators engaged by AHG).
AMG provides key management personnel to us for which it receives management fees. We paid
management fees of $670 for Fiscal 2019 (Fiscal 2018 - $696) to AMG in connection with compensation
for key management personnel. We do not expect to continue purchasing key management personnel
services from AMG in 2020. All employees involved in the AHG business previously employed by AMG
have become our employees.
In Fiscal 2019, we began to recover facility lease costs from AMG. For Fiscal 2019 we recovered $320 of
facility lease costs from AMG. We expect to continue to incur and recover facility lease costs in connection
with AMG. In Fiscal 2019, we charged AMG $12 (Fiscal 2018 - $12) for recovery of shared services costs.
Andlauer Properties and Leasing Inc.
Andlauer Properties and Leasing Inc. (“APLI”) is a subsidiary of AMG and leases certain facilities and
logistics and transportation equipment to us. We also lease facilities and logistics and transportation
equipment from arm’s length providers. During Fiscal 2019, we expensed $1,484 (Fiscal 2018 - $1,046)
for leases of logistics and transportation equipment; and $605 (Fiscal 2018 - $345) for leases of facilities
from APLI. The specific facilities that we lease from APLI are located at: 881 Bell Blvd. W, Belleville,
Ontario; 80 – 14th Avenue, Hanover, Ontario; 465 Ofield Road South, Dundas, Ontario; 605 Max Brose
Drive, London, Ontario; and 5480 61 Avenue SE, Calgary, Alberta. We expect to continue leasing
properties and equipment from APLI. In Fiscal 2019 we charged APLI $18 (Fiscal 2018 - $18) for recovery
of shared services costs.
9143-5271 Québec Inc.
9143-5271 Québec Inc. is a subsidiary of AMG and leases a facility located at 655 Desserte E. Hwy 13,
Laval Québec to the Company. We also lease facilities from arm’s length providers. During Fiscal 2019,
we expensed $1,149 (Fiscal 2018 - $1,109) for this building. We expect to continue leasing this property.
In Fiscal 2019, we charged 9143-5271 Québec Inc. $30 (Fiscal 2018 - $30) for recovery of shared services
costs.
Ready Staffing Solutions Inc.
Ready Staffing Solutions Inc. (“RSS”), a company owned by Mr. Andlauer’s spouse, provides us with
temporary agency employee services – providing hourly dock labour for our handling operations,
principally in the Greater Toronto Area (the “GTA”). We also purchase temporary agency employee
services from arm’s length providers. During Fiscal 2019, we expensed $4,153 (Fiscal 2018 - $4,176) for
purchases of temporary agency employee services from RSS. These expenses primarily relate to the cost
of the labour provided through RSS. We expect to continue purchasing temporary agency services from
RSS.
1708998 Ontario Limited (Medical Courier Services)
Medical Courier Services (“MCS”) is a subsidiary owned 80% by AMG and provides transportation
services to us, providing extended reach for shipments where we do not have our own facilities or
equipment. During Fiscal 2019, we expensed $253 (Fiscal 2018 - $236) for deliveries subcontracted to
MCS. We expect to continue subcontracting deliveries to MCS. Similarly, in Fiscal 2019 we invoiced MCS
- 27 -
for $7 (Fiscal 2018 - $4) for transportation services provided to MCS. In Fiscal 2019, we charged MCS $12
(Fiscal 2018 - $12) for recovery of shared services costs.
McAllister Courier Inc.
McAllister Courier Inc. (“MCI”) is a subsidiary owned 50% by AMG and provides transportation services
to us, providing extended reach for shipments where we do not have our own facilities or equipment. During
Fiscal 2019, we expensed $972 (Fiscal 2018 - $1,053) for deliveries subcontracted to MCI. We expect to
continue subcontracting deliveries to MCI.
TDS Logistics Ltd.
TDS Logistics Ltd. (“TDS”) is a subsidiary owned 50% by AMG and subcontracts deliveries to us, to take
advantage of efficiencies gained through coincidences of delivery. During Fiscal 2019, we charged $721
(Fiscal 2018 - $100) for deliveries subcontracted to us by TDS. We also provide TDS with certain shared
services, comprising administrative and information technology services and recover certain equipment
rental charges from TDS. During Fiscal 2019, we charged TDS $252 (Fiscal 2018 - $144) for shared
services and recovered $364 (Fiscal 2018 - $nil) in equipment rental charges. We expect to continue
providing delivery services on behalf of TDS, and shared services and equipment rentals to TDS. In Fiscal
2019, TDS began to provide transportation services to us, offering us additional capacity where we can sub-
contract deliveries to take advantage of coincidences of delivery. During Fiscal 2019, TDS charged us $558
(Fiscal 2018 – nil) for deliveries subcontracted to it by AHG. We expect to continue to subcontract
deliveries to TDS.
In Fiscal 2018 we provided TDS with facility and equipment leases, which are cost recoveries. For Fiscal
2019 we recovered $656 (Fiscal 2018 - $139) of facility lease costs from TDS. We expect to continue to
incur and recover these costs in connection with TDS.
Med Express
Med Express is a subsidiary owned 50% by AMG and provides transportation services to the Company,
providing extended reach for shipments where the Company does not have facilities or equipment. In Fiscal
2019 we purchased $1 (Fiscal 2018 – $nil) in services from Med Express.
Bourbon Street Enterprises Inc.
Bourbon Street Enterprises Inc. (“BSE”) is owned directly by Cameron Joyce, one of our directors. On July
19, 2018, AMG acquired 15% of the non-controlling equity interest held by BSE in Associated Logistics
Solutions Inc. and on June 13, 2019, purchased the remaining 15% equity interest in ALS from BSE.
D.C. Racking & Maintenance Inc.
D.C. Racking & Maintenance Inc. (“DCR”) is a subsidiary of BSE and provides warehouse racking
installation, maintenance and repairs for our healthcare logistics segment. We also purchase warehouse
racking installation, maintenance and repairs from arm’s length providers. During Fiscal 2019, we expensed
$46 (Fiscal 2018 - $64) for warehouse racking installation, maintenance and repair services provided by
DCR. We expect to continue to purchase warehouse racking installation, maintenance and repair services
from DCR.
Logiserv
- 28 -
Logiserv Inc. (“Logiserv”) is a subsidiary of BSE and provides us with warehouse racking and racking
components. We also purchase warehouse racking and racking components from arm’s length providers.
During Fiscal 2019, we capitalized $335 (Fiscal 2018 - $177) for purchases of warehouse racking. We
expect to continue to purchase warehouse racking and racking components from Logiserv.
C-GHBS Inc.
C-GHBS Inc. (“C-GHBS”) is a subsidiary of AMG and provides air travel services to us. We also purchase
air travel services from arm’s length providers. During Fiscal 2019, we purchased $329 (Fiscal 2018 – $nil)
from C-GHBS. We expect to continue to purchase air travel services from C-GHBS.
Bulldog Hockey Inc.
Bulldog Hockey Inc. (“BHI”) is a subsidiary of AMG and provides sports and entertainment services to us.
During Fiscal 2019, we purchased $25 (Fiscal 2018 - $28) of sports and entertainment services from BHI
on terms which we believe to be arm’s length. We also purchase sports and entertainment services from
arm’s length providers. We expect to continue to purchase sports and entertainment services from BHI.
- 29 -
Due from/to related parties
The chart below summarizes amounts due to or from related parties.
($CAD 000s)
Accounts receivable
Andlauer Management Group Inc.
TDS Logistics Ltd.
Andlauer Properties and Leasing Inc.
9143-5271 Quebec Inc.
Trade receivables due from related parties
Due from related parties
Andlauer Management Group Inc.
C-GHBS Inc.
Andlauer Properties and Leasing Inc.
Habdog Investments Inc.
TDS Logistics Ltd.
Total due from related parties
Accounts payable and accrued liabilities
Ready Staffing Solutions Inc.
1708998 Ontario Limited (Medical Courier Services)
McAllister Courier Inc.
TDS Logistics Ltd.
Andlauer Properties and Leasing Inc.
Andlauer Management Group Inc.
D.C. Racking & Maintenance Inc.
Logiserv Inc.
Bulldog Hockey Inc.
C-GHBS Inc.
Trade payables due to related parties
Due to related parties
M. Andlauer
TDS Logistics Ltd.
Andlauer Management Group Inc.
Total due to related parties
Critical Accounting Judgements and Estimates
As At December 31,
2018
2019
60
380
-
1
441
53
-
186
-
-
239
680
397
-
71
100
1,196
1
1
69
28
153
2,016
161
174
-
335
2,351
7
263
113
-
81
52,603
1,405
685
236
28
54,957
55,340
330
24
92
-
32
-
1
70
28
-
577
20
-
300
320
897
The preparation of the consolidated financial statements in conformity with IFRS requires management to
make judgments, estimates and assumptions about future events. These estimates and the underlying
assumptions affect the reported amounts of assets and liabilities, the disclosures about contingent assets and
liabilities, and the reported amounts of revenues and expenses and apply equally to both our healthcare
logistics segment and our specialized transportation segment. Such estimates include the expected credit
losses on accounts receivable, the useful life of long-lived assets, the Company’s incremental borrowing
rate, valuation of property, plant and equipment, valuation of goodwill and intangible assets, the
measurement of identified assets and liabilities acquired in business combinations, share-based
- 30 -
compensation arrangements, the provision for income taxes and other provisions and contingencies. These
estimates and assumptions are based on management’s best estimates and judgments. Management
evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors,
including the current economic environment, which management believes to be reasonable under the
circumstances. Management adjusts such estimates and assumptions when facts and circumstances dictate.
Actual results could differ from these estimates. Changes in those estimates and assumptions resulting from
changes in the economic environment will be reflected in the consolidated financial statements of future
periods. Information about critical judgments, assumptions and estimation uncertainties that have a
significant risk of resulting in a material adjustment within the next financial year include the following:
Determining the expected credit losses related to trade accounts receivable;
Estimating the useful life of our property, plant and equipment and determining estimates and
assumptions related to impairment tests for long-lived assets;
Estimating the useful life of our intangible assets and determining estimates and assumptions
related to impairment tests for intangibles and goodwill;
Determining the valuation of share-based compensation arrangements;
Determining estimates and assumptions in measuring deferred tax assets and liabilities;
Estimating our incremental borrowing rate in connection with measuring lease liabilities; and
Recognition and measurement of provisions and contingencies.
Significant New Accounting Standards Not Yet Adopted
Certain new accounting standards and interpretations have been published that are not mandatory for
December 31, 2019 reporting periods and that we did not adopt early. Our assessment of the impact of these
new standards and interpretations is set out below:
Amendments to IFRS 3, Business Combinations – Change in definition of business
In October 2018, the IASB issued amendments to IFRS 3 Business Combinations that seek to clarify
whether a transaction results in an asset or a business acquisition.
The amendments include an election to use a concentration test. This is a simplified assessment that results
in an asset acquisition if substantially all of the fair value of the gross assets is concentrated in a single
identifiable asset or a group of similar identifiable assets. If a preparer chooses not to apply the
concentration test, or the test is failed, then the assessment focuses on the existence of a substantive process.
The amendment applies to businesses acquired in annual reporting periods beginning on or after January 1,
2020. Earlier application is permitted. The application of this amendment is not expected to have a material
impact on our consolidated financial statements.
Amendments to IAS 1 and IAS 8 - Definition of ‘Material’
In October 2018, the IASB refined its definition of material to make it easier to understand. In the
amendment, IASB promoted the concept of ‘obscuring’ to the definition, alongside the existing references
to ‘omitting’ and ‘misstating’. Additionally, the IASB increased the threshold of ‘could influence’ to ‘could
reasonably be expected to influence’. The amendments are effective from January 1, 2020 but may be
applied earlier. The application of this amendment is not expected to have a material impact on our
consolidated financial statements.
- 31 -
Accounting Classifications and Fair Values
Our financial instruments consist of cash and cash equivalents, accounts receivable, deposits, and accounts
payable and accrued liabilities. We believe that the carrying amount of each of these items is a reasonable
approximation of fair value.
Risk Factors
For a detailed description of risk factors associated with the Company, refer to the “Risk Factors” section
of our AIF, which is available on the Company’s profile on SEDAR at www.sedar.com.
In addition to the other risks that we face, which are detailed in the AIF under the heading “Risk Factors”,
we have exposure, through our financial assets and liabilities, to the following risks from our use of financial
instruments: credit risk, liquidity risk, interest rate risk, and currency risk. Senior management monitors
risk levels and reviews risk management activities as they determine to be necessary.
Credit risk
We are exposed to credit risk in the event of non-performance by counterparties in connection with our
financial assets, namely cash and cash equivalents, accounts receivable and long-term deposits. We do not
typically obtain collateral or other security to support the accounts receivable subject to credit risk but
mitigate this risk by performing credit check procedures for new clients and monitoring credit limits for
existing clients. Thereby, we deal only with what management believes to be financially sound
counterparties and, accordingly, do not anticipate significant loss for non-performance.
The maximum exposure to credit risk for cash and cash equivalents, accounts receivable and long-term
deposits approximate the amount recorded on the consolidated balance sheets.
Liquidity risk
Liquidity risk is the risk that we will encounter difficulty in meeting the obligations associated with our
financial liabilities that are settled by delivering cash or another financial asset. Our approach to managing
liquidity is to ensure, as far as possible, that we will have sufficient liquidity to meet our liabilities when
they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking
damage to our reputation.
Our exposure to liquidity risk is dependent on the collection of accounts receivable, or raising of funds to
meet commitments and sustain operations. We control liquidity risk by management of working capital,
cash flows and the availability of borrowing facilities.
We entered into the Credit Facilities upon closing of our IPO, comprised of the Revolving Credit Facility
and the Term Facility. As at December 31, 2019, the aggregate amount outstanding under the Credit
Facilities was approximately $3.9 million under the Revolving Credit Facility and $25 million under the
Term Facility). The Credit Facilities will mature and be due and payable on December 11, 2023. The
Revolving Credit Facility is available to be drawn in Canadian dollars by way of prime rate loans, bankers’
acceptances and letters of credit, and in U.S. dollars by way of base rate loans, LIBOR based loans and
letters of credit, in each case, plus the applicable margin in effect from time to time. The Term Facility was
drawn in a single Canadian dollar advance on closing of the IPO by way of prime rate loans and bankers’
acceptances.
- 32 -
We have entered into Credit Facilities with affiliates of RBC and CIBC, comprised of a Revolving Credit
Facility in the aggregate principal amount of up to $75 million and a Term Facility in the aggregate principal
amount of up to $25 million. The Facilities are available to be drawn in Canadian dollars by way of prime
rate loans, bankers’ acceptances and letters of credit, and in U.S. dollars by way of base rate loans, LIBOR
based loans and letters of credit, in each case, plus the applicable margin in effect from time to time. In
order to support future potential growth through acquisitions, the Credit Facilities also include an accordion
feature to allow us to increase the commitment under one or both of the Credit Facilities in an aggregate
principal amount of up to $100 million, such that any amounts drawn under the accordion feature would be
in addition to the amounts ordinarily available, subject to the agreement of participating lenders and
provided that the Company is not, or would not, be in default under the Credit Facilities or in non-
compliance with any financial covenants and an event of default does not or would not exist, after giving
effect thereto and provided that all representations and warranties are true and correct immediately prior to,
and after giving effect to, such increase. As of the date of this MD&A, this accordion feature remains
uncommitted.
Our accounts payable and accrued liabilities are due and payable in the short-term.
Interest rate risk
The Company has a Revolving Credit Facility and Term Facility that each bear interest at a floating rate
subject to fluctuations in the bank prime rate. Changes in the bank prime lending rate can cause fluctuations
in interest payments and cash flows. The Company does not use derivative financial instruments to mitigate
the effect of this risk. The facilities under our Credit Facilities bear interest at prime plus 0.45% per annum.
At December 31, 2019, the interest rate was 4.4%.
Due to timing at which the Company entered into the Credit Facilities in relation to its year end, there has
been no exposure to significant interest rate fluctuations.
Currency risk
The Company enters into foreign currency purchase and sale transactions and has assets and liabilities that
are denominated in foreign currencies and thus are exposed to the financial risk of earnings fluctuations
arising from changes in foreign exchange rates and the degree of volatility of these rates. The Company
does not currently use derivative instruments to reduce its exposure to foreign currency risk.
Outstanding Share Data
Our authorized share capital consists of an unlimited number of Subordinate Voting Shares, an unlimited
number of Multiple Voting Shares and an unlimited number of preferred shares, issuable in series. As at
March 12, 2020, there were 12,500,000 Subordinate Voting Shares issued and outstanding, 25,100,000
Multiple Voting Shares issued and outstanding (each of which is convertible into Subordinate Voting
Shares on a one-for-one basis), and no preferred shares issued and outstanding. In addition, as at such date
we had 1,650,000 options issued and outstanding under the Company’s omnibus incentive plan, each of
which can be exercised or settled for one Subordinate Voting Share. As of the date hereof, AMG holds all
of the Multiple Voting Shares and 75,000 of the Subordinate Voting Shares, representing approximately
67% of the issued and outstanding Shares and 89% of the voting power attached to all of the Shares.
Subject to financial results, capital requirements, available cash flow, corporate law requirements and any
other factors that the board of directors of the Company may consider relevant, the Company expects to
declare a quarterly dividend on the Subordinate Voting Shares and Multiple Voting Shares equal to
- 33 -
approximately $0.05 per share on an ongoing basis. The first dividend that will be payable will be the
dividend for the period beginning on December 11, 2019, and ending on March 31, 2020 to shareholders
of record on March 31, 2020. This first dividend will be equal to an aggregate amount of approximately
$2,288,712 (or $0.06087 per Share). Dividends will be declared and paid in arrears. The amount and timing
of the payment of any dividends are not guaranteed and are subject to the discretion of our board of
directors.
Disclosure Controls and Procedures and Internal Controls Over Financial Reporting
In accordance with Item 4.3 of National Instrument 52-109 - Certification of Disclosure in Issuers’ Annual
and Interim Filings (“NI 52-109”), the Company will file an annual certificate in the Form 52-109F1 -
IPO/RTO relating to its AIF, annual financial statements and the accompanying notes and this MD&A
because it is the first financial year that has ended after the Company became a reporting issuer.
In particular, the certifying officers filing the certificate in the Form 52-109F1 - IPO/RTO required under
NI 52-109 are not making any representations relating to the establishment and maintenance of:
controls and other procedures designed to provide reasonable assurance that information
required to be disclosed by the issuer in its annual filings, interim filings or other reports filed
or submitted under securities legislation is recorded, processed, summarized and reported
within the time periods specified in securities legislation; and
a process to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with the
Company’s GAAP.
Additional Information
Additional information about the Company can be found on our profile on SEDAR at www.sedar.com or
on our website at www.andlauerhealthcare.com. The Company’s AIF for Fiscal 2019 is available on our
profile on SEDAR at www.sedar.com.
Consolidated Financial Statements of
ANDLAUER HEALTHCARE
GROUP INC.
For the years ended December 31, 2019 and 2018
KPMG LLP
Commerce Place
21 King Street West, Suite 700
Hamilton ON L8P 4W7
Canada
Telephone (905) 523-8200
Fax (905) 523-2222
INDEPENDENT AUDITORS’ REPORT
To the Shareholders of Andlauer Healthcare Group Inc.
Opinion
We have audited the consolidated financial statements of Andlauer Healthcare Group
Inc. (the “Entity”), which comprise:
(cid:120)
(cid:120)
(cid:120)
(cid:120)
(cid:120)
the consolidated balance sheets as at December 31, 2019 and December 31,
2018
the consolidated statements of income and comprehensive income for the years
ended December 31, 2019 and December 31, 2018
the consolidated statements of changes in equity for the years ended December
31, 2019 and December 31, 2018
the consolidated statements of cash flows for the years ended December 31, 2019
and December 31, 2018
and notes to the consolidated financial statements, including a summary of
significant accounting policies
(hereinafter referred to as the “financial statements”).
In our opinion, the accompanying financial statements present fairly, in all material
respects, the financial position of the Entity as at December 31, 2019 and December
31, 2018, and its financial performance and its cash flows for the years ended
December 31, 2019 and December 31, 2018 in accordance with International Financial
Reporting Standards (“IFRS”).
Basis for Opinion
We conducted our audit in accordance with Canadian generally accepted auditing
standards. Our responsibilities under those standards are further described in the
“Auditors’ Responsibilities for the Audit of the Financial Statements” section of our
auditors’ report.
KPMG LLP is a Canadian limited liability partnership and a member firm of the KPMG network of independent
member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity.
KPMG Canada provides services to KPMG LLP.
We are independent of the Entity in accordance with the ethical requirements that are
relevant to our audit of the financial statements in Canada and we have fulfilled our
ethical responsibilities in accordance with these requirements.
We believe that the audit evidence we have obtained is sufficient and appropriate to
provide a basis for our opinion.
Emphasis of Matter — Basis of Presentation
We draw attention to Note 2 to the financial statements, which describes the basis of
presentation, including the approach to and the purpose for preparing the financial
statements including the comparative information.
Our opinion is not modified in respect of this matter.
Other Information
Management is responsible for the other information. Other information comprises:
(cid:120) the information included in Management’s Discussion and Analysis filed with the
relevant Canadian Securities Commissions.
(cid:120) the information, other than the financial statements and the auditors’ report thereon,
included in a document likely to be entitled “Annual Report”.
Our opinion on the financial statements does not cover the other information and we
do not and will not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the
other information identified above and, in doing so, consider whether the other
information is materially inconsistent with the financial statements or our knowledge
obtained in the audit and remain alert for indications that the other information appears
to be materially misstated.
We obtained the information included in Management’s Discussion and Analysis filed
with the relevant Canadian Securities Commissions as at the date of this auditors’
report. If, based on the work that we have performed on this other information, we
conclude that there is a material misstatement of this other information, we are required
to report that fact in the auditors’ report.
We have nothing to report in this regard.
The information, other than the financial statements and the auditors’ report thereon,
included in a document likely to be entitled “Annual Report” is expected to be made
available to us after the date of this auditors’ report. If, based on the work we will
perform on this other information, we conclude that there is a material misstatement of
this other information, we are required to report that fact to those charged with
governance.
Responsibilities of Management and Those Charged with Governance for the
Financial Statements
Management is responsible for the preparation and fair presentation of the financial
statements in accordance with International Financial Reporting Standards (IFRS), and
for such internal control as management determines is necessary to enable the
preparation of financial statements that are free from material misstatement, whether
due to fraud or error.
In preparing the financial statements, management is responsible for assessing the
Entity’s ability to continue as a going concern, disclosing as applicable, matters related
to going concern and using the going concern basis of accounting unless management
either intends to liquidate the Entity or to cease operations, or has no realistic
alternative but to do so.
Those charged with governance are responsible for overseeing the Entity’s financial
reporting process.
Auditors’ Responsibilities for the Audit of the Financial Statements
Our objectives are to obtain reasonable assurance about whether the financial
statements as a whole are free from material misstatement, whether due to fraud or
error, and to issue an auditors’ report that includes our opinion.
Reasonable assurance is a high level of assurance, but is not a guarantee that an audit
conducted in accordance with Canadian generally accepted auditing standards will
always detect a material misstatement when it exists.
Misstatements can arise from fraud or error and are considered material if, individually
or in the aggregate, they could reasonably be expected to influence the economic
decisions of users taken on the basis of the financial statements.
As part of an audit in accordance with Canadian generally accepted auditing
standards, we exercise professional judgment and maintain professional skepticism
throughout the audit.
We also:
(cid:120)
Identify and assess the risks of material misstatement of the financial statements,
whether due to fraud or error, design and perform audit procedures responsive to
those risks, and obtain audit evidence that is sufficient and appropriate to provide
a basis for our opinion.
The risk of not detecting a material misstatement resulting from fraud is higher than
for one resulting from error, as fraud may involve collusion, forgery, intentional
omissions, misrepresentations, or the override of internal control.
(cid:120) Obtain an understanding of internal control relevant to the audit in order to design
audit procedures that are appropriate in the circumstances, but not for the purpose
of expressing an opinion on the effectiveness of the Entity's internal control.
(cid:120) Evaluate the appropriateness of accounting policies used and the reasonableness
of accounting estimates and related disclosures made by management.
(cid:120) Conclude on the appropriateness of management's use of the going concern basis
of accounting and, based on the audit evidence obtained, whether a material
uncertainty exists related to events or conditions that may cast significant doubt on
the Entity's ability to continue as a going concern. If we conclude that a material
uncertainty exists, we are required to draw attention in our auditors’ report to the
related disclosures in the financial statements or, if such disclosures are
inadequate, to modify our opinion. Our conclusions are based on the audit
evidence obtained up to the date of our auditors’ report. However, future events or
conditions may cause the Entity to cease to continue as a going concern.
(cid:120) Evaluate the overall presentation, structure and content of the financial statements,
including the disclosures, and whether the financial statements represent the
underlying transactions and events in a manner that achieves fair presentation.
(cid:120) Communicate with those charged with governance regarding, among other
matters, the planned scope and timing of the audit and significant audit findings,
including any significant deficiencies in internal control that we identify during our
audit.
(cid:120) Provide those charged with governance with a statement that we have complied
with relevant ethical requirements regarding independence, and communicate with
them all relationships and other matters that may reasonably be thought to bear
on our independence, and where applicable, related safeguards.
(cid:120) Obtain sufficient appropriate audit evidence regarding the financial information of
the entities or business activities within the consolidated entity to express an
opinion on the financial statements. We are responsible for the direction,
supervision and performance of the group audit. We remain solely responsible for
our audit opinion.
The engagement partner on the audit resulting in this auditors’ report is John J. Pryke
Chartered Professional Accountants, Licensed Public Accountants
Hamilton, Canada
March 12, 2020
(cid:4)(cid:374)(cid:282)(cid:367)(cid:258)(cid:437)(cid:286)(cid:396)(cid:3)(cid:44)(cid:286)(cid:258)(cid:367)(cid:410)(cid:346)(cid:272)(cid:258)(cid:396)(cid:286)(cid:3)(cid:39)(cid:396)(cid:381)(cid:437)(cid:393)(cid:3)(cid:47)(cid:374)(cid:272)(cid:856)(cid:3)
(cid:18)(cid:381)(cid:374)(cid:400)(cid:381)(cid:367)(cid:349)(cid:282)(cid:258)(cid:410)(cid:286)(cid:282)(cid:3)(cid:17)(cid:258)(cid:367)(cid:258)(cid:374)(cid:272)(cid:286)(cid:3)(cid:94)(cid:346)(cid:286)(cid:286)(cid:410)(cid:400)(cid:3)
(cid:4)(cid:400)(cid:3)(cid:258)(cid:410)(cid:3)(cid:24)(cid:286)(cid:272)(cid:286)(cid:373)(cid:271)(cid:286)(cid:396)(cid:3)(cid:1007)(cid:1005)(cid:853)(cid:3)(cid:1006)(cid:1004)(cid:1005)(cid:1013)(cid:3)(cid:258)(cid:374)(cid:282)(cid:3)(cid:1006)(cid:1004)(cid:1005)(cid:1012)(cid:3)
(cid:894)(cid:47)(cid:374)(cid:3)(cid:410)(cid:346)(cid:381)(cid:437)(cid:400)(cid:258)(cid:374)(cid:282)(cid:400)(cid:3)(cid:381)(cid:296)(cid:3)(cid:18)(cid:258)(cid:374)(cid:258)(cid:282)(cid:349)(cid:258)(cid:374)(cid:3)(cid:282)(cid:381)(cid:367)(cid:367)(cid:258)(cid:396)(cid:400)(cid:853)(cid:3)(cid:286)(cid:454)(cid:272)(cid:286)(cid:393)(cid:410)(cid:3)(cid:400)(cid:346)(cid:258)(cid:396)(cid:286)(cid:400)(cid:853)(cid:3)(cid:400)(cid:346)(cid:258)(cid:396)(cid:286)(cid:3)(cid:393)(cid:396)(cid:349)(cid:272)(cid:286)(cid:3)(cid:258)(cid:374)(cid:282)(cid:3)(cid:286)(cid:258)(cid:396)(cid:374)(cid:349)(cid:374)(cid:336)(cid:400)(cid:3)(cid:393)(cid:286)(cid:396)(cid:3)(cid:400)(cid:346)(cid:258)(cid:396)(cid:286)(cid:895)(cid:3)
(cid:4)(cid:400)(cid:400)(cid:286)(cid:410)(cid:400)(cid:3)
(cid:18)(cid:437)(cid:396)(cid:396)(cid:286)(cid:374)(cid:410)(cid:3)(cid:258)(cid:400)(cid:400)(cid:286)(cid:410)(cid:400)(cid:3)
(cid:18)(cid:258)(cid:400)(cid:346)(cid:3)(cid:258)(cid:374)(cid:282)(cid:3)(cid:272)(cid:258)(cid:400)(cid:346)(cid:3)(cid:286)(cid:395)(cid:437)(cid:349)(cid:448)(cid:258)(cid:367)(cid:286)(cid:374)(cid:410)(cid:400)(cid:3)
(cid:4)(cid:272)(cid:272)(cid:381)(cid:437)(cid:374)(cid:410)(cid:400)(cid:3)(cid:396)(cid:286)(cid:272)(cid:286)(cid:349)(cid:448)(cid:258)(cid:271)(cid:367)(cid:286)(cid:3)
(cid:47)(cid:374)(cid:448)(cid:286)(cid:374)(cid:410)(cid:381)(cid:396)(cid:349)(cid:286)(cid:400)(cid:3)
(cid:87)(cid:396)(cid:286)(cid:393)(cid:258)(cid:349)(cid:282)(cid:3)(cid:286)(cid:454)(cid:393)(cid:286)(cid:374)(cid:400)(cid:286)(cid:400)(cid:3)(cid:258)(cid:374)(cid:282)(cid:3)(cid:381)(cid:410)(cid:346)(cid:286)(cid:396)(cid:3)
(cid:24)(cid:437)(cid:286)(cid:3)(cid:296)(cid:396)(cid:381)(cid:373)(cid:3)(cid:396)(cid:286)(cid:367)(cid:258)(cid:410)(cid:286)(cid:282)(cid:3)(cid:393)(cid:258)(cid:396)(cid:410)(cid:349)(cid:286)(cid:400)(cid:3)
(cid:24)(cid:437)(cid:286)(cid:3)(cid:296)(cid:396)(cid:381)(cid:373)(cid:3)(cid:286)(cid:373)(cid:393)(cid:367)(cid:381)(cid:455)(cid:286)(cid:286)(cid:3)(cid:410)(cid:396)(cid:437)(cid:400)(cid:410)(cid:3)
(cid:69)(cid:381)(cid:374)(cid:882)(cid:272)(cid:437)(cid:396)(cid:396)(cid:286)(cid:374)(cid:410)(cid:3)(cid:258)(cid:400)(cid:400)(cid:286)(cid:410)(cid:400)(cid:3)
(cid:62)(cid:381)(cid:374)(cid:336)(cid:882)(cid:410)(cid:286)(cid:396)(cid:373)(cid:3)(cid:282)(cid:286)(cid:393)(cid:381)(cid:400)(cid:349)(cid:410)(cid:400)(cid:3)
(cid:87)(cid:396)(cid:381)(cid:393)(cid:286)(cid:396)(cid:410)(cid:455)(cid:853)(cid:3)(cid:393)(cid:367)(cid:258)(cid:374)(cid:410)(cid:3)(cid:258)(cid:374)(cid:282)(cid:3)(cid:286)(cid:395)(cid:437)(cid:349)(cid:393)(cid:373)(cid:286)(cid:374)(cid:410)(cid:3)
(cid:39)(cid:381)(cid:381)(cid:282)(cid:449)(cid:349)(cid:367)(cid:367)(cid:3)(cid:258)(cid:374)(cid:282)(cid:3)(cid:349)(cid:374)(cid:410)(cid:258)(cid:374)(cid:336)(cid:349)(cid:271)(cid:367)(cid:286)(cid:3)(cid:258)(cid:400)(cid:400)(cid:286)(cid:410)(cid:400)(cid:3)
(cid:24)(cid:286)(cid:296)(cid:286)(cid:396)(cid:396)(cid:286)(cid:282)(cid:3)(cid:349)(cid:374)(cid:272)(cid:381)(cid:373)(cid:286)(cid:3)(cid:410)(cid:258)(cid:454)(cid:286)(cid:400)(cid:3)
(cid:100)(cid:381)(cid:410)(cid:258)(cid:367)(cid:3)(cid:4)(cid:400)(cid:400)(cid:286)(cid:410)(cid:400)(cid:3)
(cid:62)(cid:349)(cid:258)(cid:271)(cid:349)(cid:367)(cid:349)(cid:410)(cid:349)(cid:286)(cid:400)(cid:3)(cid:258)(cid:374)(cid:282)(cid:3)(cid:28)(cid:395)(cid:437)(cid:349)(cid:410)(cid:455)(cid:3)
(cid:18)(cid:437)(cid:396)(cid:396)(cid:286)(cid:374)(cid:410)(cid:3)(cid:367)(cid:349)(cid:258)(cid:271)(cid:349)(cid:367)(cid:349)(cid:410)(cid:349)(cid:286)(cid:400)(cid:3)
(cid:90)(cid:286)(cid:448)(cid:381)(cid:367)(cid:448)(cid:349)(cid:374)(cid:336)(cid:3)(cid:272)(cid:396)(cid:286)(cid:282)(cid:349)(cid:410)(cid:3)(cid:296)(cid:258)(cid:272)(cid:349)(cid:367)(cid:349)(cid:410)(cid:455)(cid:3)
(cid:4)(cid:272)(cid:272)(cid:381)(cid:437)(cid:374)(cid:410)(cid:400)(cid:3)(cid:393)(cid:258)(cid:455)(cid:258)(cid:271)(cid:367)(cid:286)(cid:3)(cid:258)(cid:374)(cid:282)(cid:3)(cid:258)(cid:272)(cid:272)(cid:396)(cid:437)(cid:286)(cid:282)(cid:3)(cid:367)(cid:349)(cid:258)(cid:271)(cid:349)(cid:367)(cid:349)(cid:410)(cid:349)(cid:286)(cid:400)(cid:3)
(cid:18)(cid:437)(cid:396)(cid:396)(cid:286)(cid:374)(cid:410)(cid:3)(cid:393)(cid:381)(cid:396)(cid:410)(cid:349)(cid:381)(cid:374)(cid:3)(cid:381)(cid:296)(cid:3)(cid:367)(cid:286)(cid:258)(cid:400)(cid:286)(cid:3)(cid:367)(cid:349)(cid:258)(cid:271)(cid:349)(cid:367)(cid:349)(cid:410)(cid:349)(cid:286)(cid:400)(cid:3)
(cid:47)(cid:374)(cid:272)(cid:381)(cid:373)(cid:286)(cid:3)(cid:410)(cid:258)(cid:454)(cid:286)(cid:400)(cid:3)(cid:393)(cid:258)(cid:455)(cid:258)(cid:271)(cid:367)(cid:286)(cid:3)
(cid:62)(cid:381)(cid:374)(cid:336)(cid:882)(cid:410)(cid:286)(cid:396)(cid:373)(cid:3)(cid:367)(cid:349)(cid:258)(cid:271)(cid:349)(cid:367)(cid:349)(cid:410)(cid:349)(cid:286)(cid:400)(cid:3)
(cid:62)(cid:286)(cid:258)(cid:400)(cid:286)(cid:3)(cid:367)(cid:349)(cid:258)(cid:271)(cid:349)(cid:367)(cid:349)(cid:410)(cid:349)(cid:286)(cid:400)(cid:3)
(cid:24)(cid:286)(cid:296)(cid:286)(cid:396)(cid:396)(cid:286)(cid:282)(cid:3)(cid:349)(cid:374)(cid:272)(cid:381)(cid:373)(cid:286)(cid:3)(cid:410)(cid:258)(cid:454)(cid:286)(cid:400)(cid:3)
(cid:24)(cid:437)(cid:286)(cid:3)(cid:410)(cid:381)(cid:3)(cid:396)(cid:286)(cid:367)(cid:258)(cid:410)(cid:286)(cid:282)(cid:3)(cid:393)(cid:258)(cid:396)(cid:410)(cid:349)(cid:286)(cid:400)(cid:3)
(cid:100)(cid:286)(cid:396)(cid:373)(cid:3)(cid:296)(cid:258)(cid:272)(cid:349)(cid:367)(cid:349)(cid:410)(cid:455)(cid:3)
(cid:100)(cid:381)(cid:410)(cid:258)(cid:367)(cid:3)(cid:62)(cid:349)(cid:258)(cid:271)(cid:349)(cid:367)(cid:349)(cid:410)(cid:349)(cid:286)(cid:400)(cid:3)
(cid:28)(cid:395)(cid:437)(cid:349)(cid:410)(cid:455)(cid:3)
(cid:100)(cid:381)(cid:410)(cid:258)(cid:367)(cid:3)(cid:374)(cid:286)(cid:410)(cid:3)(cid:393)(cid:258)(cid:396)(cid:286)(cid:374)(cid:410)(cid:3)(cid:349)(cid:374)(cid:448)(cid:286)(cid:400)(cid:410)(cid:373)(cid:286)(cid:374)(cid:410)(cid:3)
(cid:69)(cid:381)(cid:374)(cid:882)(cid:272)(cid:381)(cid:374)(cid:410)(cid:396)(cid:381)(cid:367)(cid:367)(cid:349)(cid:374)(cid:336)(cid:3)(cid:349)(cid:374)(cid:410)(cid:286)(cid:396)(cid:286)(cid:400)(cid:410)(cid:3)
(cid:18)(cid:381)(cid:373)(cid:373)(cid:381)(cid:374)(cid:3)(cid:400)(cid:346)(cid:258)(cid:396)(cid:286)(cid:3)(cid:272)(cid:258)(cid:393)(cid:349)(cid:410)(cid:258)(cid:367)(cid:3)
(cid:18)(cid:381)(cid:374)(cid:410)(cid:396)(cid:349)(cid:271)(cid:437)(cid:410)(cid:286)(cid:282)(cid:3)(cid:400)(cid:437)(cid:396)(cid:393)(cid:367)(cid:437)(cid:400)(cid:3)
(cid:68)(cid:286)(cid:396)(cid:336)(cid:286)(cid:396)(cid:3)(cid:396)(cid:286)(cid:400)(cid:286)(cid:396)(cid:448)(cid:286)(cid:3)
(cid:24)(cid:286)(cid:296)(cid:349)(cid:272)(cid:349)(cid:410)(cid:3)
(cid:18)(cid:381)(cid:373)(cid:373)(cid:349)(cid:410)(cid:373)(cid:286)(cid:374)(cid:410)(cid:400)(cid:3)(cid:258)(cid:374)(cid:282)(cid:3)(cid:272)(cid:381)(cid:374)(cid:410)(cid:349)(cid:374)(cid:336)(cid:286)(cid:374)(cid:272)(cid:349)(cid:286)(cid:400)(cid:3)
(cid:94)(cid:437)(cid:271)(cid:400)(cid:286)(cid:395)(cid:437)(cid:286)(cid:374)(cid:410)(cid:3)(cid:286)(cid:448)(cid:286)(cid:374)(cid:410)(cid:3)
(cid:100)(cid:381)(cid:410)(cid:258)(cid:367)(cid:3)(cid:62)(cid:349)(cid:258)(cid:271)(cid:349)(cid:367)(cid:349)(cid:410)(cid:349)(cid:286)(cid:400)(cid:3)(cid:258)(cid:374)(cid:282)(cid:3)(cid:28)(cid:395)(cid:437)(cid:349)(cid:410)(cid:455)(cid:3)
(cid:94)(cid:286)(cid:286)(cid:3)(cid:258)(cid:272)(cid:272)(cid:381)(cid:373)(cid:393)(cid:258)(cid:374)(cid:455)(cid:349)(cid:374)(cid:336)(cid:3)(cid:374)(cid:381)(cid:410)(cid:286)(cid:400)(cid:3)(cid:410)(cid:381)(cid:3)(cid:272)(cid:381)(cid:374)(cid:400)(cid:381)(cid:367)(cid:349)(cid:282)(cid:258)(cid:410)(cid:286)(cid:282)(cid:3)(cid:296)(cid:349)(cid:374)(cid:258)(cid:374)(cid:272)(cid:349)(cid:258)(cid:367)(cid:3)(cid:400)(cid:410)(cid:258)(cid:410)(cid:286)(cid:373)(cid:286)(cid:374)(cid:410)(cid:400)(cid:856)(cid:3)
(cid:75)(cid:374)(cid:3)(cid:271)(cid:286)(cid:346)(cid:258)(cid:367)(cid:296)(cid:3)(cid:381)(cid:296)(cid:3)(cid:410)(cid:346)(cid:286)(cid:3)(cid:17)(cid:381)(cid:258)(cid:396)(cid:282)(cid:855)(cid:3)
(cid:3)(cid:3)(cid:3)(cid:919)(cid:87)(cid:286)(cid:410)(cid:286)(cid:396)(cid:3)(cid:58)(cid:286)(cid:367)(cid:367)(cid:286)(cid:455)(cid:919)
(cid:24)(cid:349)(cid:396)(cid:286)(cid:272)(cid:410)(cid:381)(cid:396)
(cid:919)(cid:100)(cid:346)(cid:381)(cid:373)(cid:258)(cid:400)(cid:3)G. (cid:116)(cid:286)(cid:367)(cid:367)(cid:374)(cid:286)(cid:396)(cid:919)
(cid:24)(cid:349)(cid:396)(cid:286)(cid:272)(cid:410)(cid:381)(cid:396)
(cid:69)(cid:381)(cid:410)(cid:286)(cid:3)(cid:3)
(cid:24)(cid:286)(cid:272)(cid:286)(cid:373)(cid:271)(cid:286)(cid:396)(cid:3)(cid:1007)(cid:1005)(cid:853)(cid:3)
(cid:1006)(cid:1004)(cid:1005)(cid:1013)(cid:3)
(cid:24)(cid:286)(cid:272)(cid:286)(cid:373)(cid:271)(cid:286)(cid:396)(cid:3)(cid:1007)(cid:1005)(cid:853)(cid:3)
(cid:1006)(cid:1004)(cid:1005)(cid:1012)(cid:3)
(cid:1009)(cid:3)
(cid:1010)(cid:3)
(cid:1011)(cid:3)
(cid:1006)(cid:1005)(cid:3)
(cid:1006)(cid:3)
(cid:1012)(cid:3)
(cid:1013)(cid:3)
(cid:1005)(cid:1011)(cid:3)
(cid:1005)(cid:1005)(cid:3)
(cid:1005)(cid:1004)(cid:3)
(cid:1005)(cid:1012)(cid:3)
(cid:1005)(cid:1012)(cid:3)
(cid:1005)(cid:1011)(cid:3)
(cid:1006)(cid:1005)(cid:3)
(cid:1005)(cid:1005)(cid:3)
(cid:1006)(cid:3)
(cid:1005)(cid:1013)(cid:3)
(cid:1005)(cid:1007)(cid:3)
(cid:1005)(cid:1009)(cid:3)
(cid:1006)(cid:3)
(cid:1006)(cid:1004)(cid:3)
(cid:1006)(cid:1007)(cid:3)
(cid:936)(cid:3)
(cid:936)(cid:3)
(cid:1005)(cid:1012)(cid:853)(cid:1011)(cid:1005)(cid:1006)(cid:3)
(cid:1009)(cid:1005)(cid:853)(cid:1004)(cid:1010)(cid:1004)(cid:3)
(cid:1005)(cid:853)(cid:1004)(cid:1011)(cid:1005)(cid:3)
(cid:1006)(cid:853)(cid:1007)(cid:1004)(cid:1011)(cid:3)
(cid:1006)(cid:1007)(cid:1013)(cid:3)
(cid:1005)(cid:1007)(cid:853)(cid:1012)(cid:1011)(cid:1009)(cid:3)
(cid:1012)(cid:1011)(cid:853)(cid:1006)(cid:1010)(cid:1008)(cid:3)
(cid:1013)(cid:1007)(cid:1012)(cid:3)
(cid:1005)(cid:1004)(cid:1007)(cid:853)(cid:1007)(cid:1006)(cid:1010)(cid:3)
(cid:1006)(cid:1005)(cid:853)(cid:1008)(cid:1006)(cid:1005)(cid:3)
(cid:1008)(cid:1010)(cid:3)
(cid:1009)(cid:1007)(cid:853)(cid:1010)(cid:1009)(cid:1011)(cid:3)
(cid:1008)(cid:1012)(cid:853)(cid:1008)(cid:1007)(cid:1004)(cid:3)
(cid:1005)(cid:853)(cid:1007)(cid:1010)(cid:1010)(cid:3)
(cid:1005)(cid:853)(cid:1008)(cid:1008)(cid:1012)(cid:3)
(cid:1009)(cid:1008)(cid:853)(cid:1013)(cid:1009)(cid:1011)(cid:3)
(cid:882)(cid:3)
(cid:1005)(cid:1009)(cid:1013)(cid:853)(cid:1012)(cid:1009)(cid:1012)(cid:3)
(cid:1011)(cid:1005)(cid:1012)(cid:3)
(cid:1013)(cid:1005)(cid:853)(cid:1012)(cid:1008)(cid:1011)(cid:3)
(cid:1006)(cid:1007)(cid:853)(cid:1010)(cid:1013)(cid:1008)(cid:3)
(cid:1008)(cid:1010)(cid:1004)(cid:3)
(cid:936)(cid:3)
(cid:1006)(cid:1005)(cid:1006)(cid:853)(cid:1013)(cid:1013)(cid:1009)(cid:3)
(cid:936)(cid:3)
(cid:1006)(cid:1011)(cid:1010)(cid:853)(cid:1009)(cid:1011)(cid:1011)(cid:3)
(cid:936)(cid:3)
(cid:936)(cid:3)
(cid:1007)(cid:853)(cid:1013)(cid:1006)(cid:1013)(cid:3)
(cid:1006)(cid:1008)(cid:853)(cid:1013)(cid:1008)(cid:1006)(cid:3)
(cid:1005)(cid:1013)(cid:853)(cid:1005)(cid:1006)(cid:1013)(cid:3)
(cid:1012)(cid:853)(cid:1010)(cid:1013)(cid:1009)(cid:3)
(cid:1009)(cid:1010)(cid:853)(cid:1010)(cid:1013)(cid:1009)(cid:3)
(cid:1010)(cid:1013)(cid:853)(cid:1009)(cid:1012)(cid:1008)(cid:3)
(cid:1007)(cid:1006)(cid:1005)(cid:3)
(cid:1007)(cid:1007)(cid:1009)(cid:3)
(cid:1006)(cid:1008)(cid:853)(cid:1009)(cid:1009)(cid:1009)(cid:3)
(cid:882)(cid:3)
(cid:1006)(cid:1011)(cid:853)(cid:1004)(cid:1013)(cid:1010)(cid:3)
(cid:1005)(cid:1011)(cid:853)(cid:1013)(cid:1008)(cid:1004)(cid:3)
(cid:1008)(cid:1005)(cid:3)
(cid:1008)(cid:1009)(cid:853)(cid:1004)(cid:1011)(cid:1011)(cid:3)
(cid:1010)(cid:1005)(cid:853)(cid:1004)(cid:1012)(cid:1004)(cid:3)
(cid:1007)(cid:1011)(cid:1006)(cid:3)
(cid:1007)(cid:1006)(cid:1004)(cid:3)
(cid:882)(cid:3)
(cid:1005)(cid:1009)(cid:1005)(cid:853)(cid:1008)(cid:1013)(cid:1004)(cid:3)
(cid:1005)(cid:1004)(cid:1010)(cid:853)(cid:1012)(cid:1008)(cid:1013)(cid:3)
(cid:882)
(cid:882)
(cid:1009)(cid:1008)(cid:1013)(cid:853)(cid:1010)(cid:1011)(cid:1013)(cid:3)
(cid:1005)(cid:853)(cid:1007)(cid:1013)(cid:1008)(cid:3)
(cid:894)(cid:1008)(cid:1012)(cid:1012)(cid:853)(cid:1013)(cid:1005)(cid:1010)(cid:895)(cid:3)
(cid:894)(cid:1010)(cid:1009)(cid:1006)(cid:895)
(cid:1010)(cid:1005)(cid:853)(cid:1009)(cid:1004)(cid:1009)(cid:3)
(cid:1005)(cid:1010)(cid:1007)(cid:853)(cid:1012)(cid:1005)(cid:1005)
(cid:1009)(cid:853)(cid:1013)(cid:1005)(cid:1011)
(cid:882)(cid:3)
(cid:882)(cid:3)
(cid:882)(cid:3)
(cid:882)
(cid:1005)(cid:1010)(cid:1013)(cid:853)(cid:1011)(cid:1006)(cid:1012)(cid:3)
(cid:936)(cid:3)
(cid:1006)(cid:1005)(cid:1006)(cid:853)(cid:1013)(cid:1013)(cid:1009)(cid:3)
(cid:936)(cid:3)
(cid:1006)(cid:1011)(cid:1010)(cid:853)(cid:1009)(cid:1011)(cid:1011)(cid:3)
(cid:87)(cid:258)(cid:336)(cid:286)(cid:3)(cid:878)(cid:3)(cid:1005)(cid:3)
Andlauer Healthcare Group Inc.
Consolidated Statements of Income and Comprehensive Income
For the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
Revenue
Operating Expenses
Cost of transportation and services
Direct operating expenses
Selling, general and administrative expenses
Depreciation and amortization
Operating Income
Other income (expense)
Interest income
Interest expense
Income before income taxes
Current income tax expense
Deferred income tax expense (recovery)
Net income and comprehensive income
Net income attributable to:
Shareholders of the Company
Non-controlling interests
Net earnings per share attributable to the
Common Shareholders of the Company:
Basic earnings per share
Diluted earnings per share
Note
December 31,
2019
December 31,
2018
16
$
289,988
$
277,010
121,405
74,792
23,092
25,706
244,995
116,780
74,190
21,683
23,491
236,144
44,993
40,866
(145)
1,004
(3,503)
19
879
(3,048)
42,349
38,716
11,641
363
12,004
10,533
(2)
10,531
30,345
28,185
29,773
572
30,345
$
26,723
1,462
28,185
0.79
0.79
N/A
N/A
17
17
19
14
14
$
$
$
See accompanying notes to consolidated financial statements.
Page | 2
Andlauer Healthcare Group Inc.
Consolidated Statements of Changes in Equity
For the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
Attributable to Common Shareholders of the Company
Number of
shares
(thousands)
(note 13)
-
Share
capital
(notes 1, 13)
$
-
Merger
reserve
(note 2)
-
$
Contributed
surplus
(note 15)
-
$
Deficit
$
Balance at December 31, 2017
Net income for the year
Distributions and dividends
Adjustment on acquisition of NCI
Balance at December 31, 2018
Net income for the period
Distributions and dividends1
Adjustment on acquisition of NCI
Balance at December 10, 2019
Net income and comprehensive
income for the period
December 11-31, 2019
Shares issued in connection with
the acquisition of the AHG
Entities
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
26,100
391,500
-
-
-
-
-
-
-
-
-
-
Acquisition of the AHG Entities
-
-
(488,916)
Shares issued in connection with
the initial public offering
Transaction costs
Share-based compensation
11,500
172,500
-
-
(14,321)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1,394
Total net
parent
investment
(note 2)
$ 157,338
Non-
controlling
interests
(note 19)
$ 10,205
Total equity
$ 167,543
26,723
1,462
28,185
(25,850)
(150)
(26,000)
5,600
(5,600)
-
163,811
5,917
169,728
30,425
572
30,997
(112,016)
-
(112,016)
6,489
(6,489)
-
88,709
-
88,709
-
-
-
-
-
-
-
-
-
(652)
-
-
-
-
-
-
-
(88,709)
-
-
-
-
$
-
-
-
-
-
-
-
(652)
391,500
(577,625)
172,500
(14,321)
1,394
$ 61,505
Balance at December 31, 2019
37,600
$ 549,679
$ (488,916)
$
1,394
$
(652)
$
1Distributions and dividends of $112,016 in 2019 includes income tax of $9,379 charged to net parent investment.
See accompanying notes to consolidated financial statements.
Page | 3
Andlauer Healthcare Group Inc.
Consolidated Statements of Cash Flow
For the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
Operating activities
Net income for the year
Changes not involving cash:
Depreciation and amortization
Share-based compensation
Deferred income tax expense (recovery)
Loss on disposal of property, plant and equipment
Changes in non-cash operating working capital:
Accounts receivable
Inventories
Accounts payable and accrued liabilities
Income taxes payable
Net change in other operating working capital balances
Cash flows from operating activities
Financing activities
Distributions to related parties
Principal repayments on lease liabilities
Net change in related party balances
Loan receivable from employee trust
Proceeds from revolving credit facility
Proceeds from term facility
Repayment of revolving credit facility
Net financing costs on credit facilities
Proceeds from issuance of share capital
Transaction costs recorded in share capital
Repayment of promissory note
Cash flows used in financing activities
Investing activities
Purchase of property, plant and equipment
Proceeds on disposal of property, plant and equipment
Purchase of intangible assets
Cash flows used in investing activities
December 31,
2019
December 31,
2018
Note
$
30,345
$
28,185
15
17
2
18
2
11
11
11
11
13
1
2
9
25,706
1,394
363
107
57,915
(2,630)
295
(2,154)
8,654
(1,079)
61,001
(112,016)
(19,161)
54,733
(13,875)
25,000
25,000
(21,071)
(445)
172,500
(14,321)
(186,125)
(89,781)
(5,935)
-
(230)
(6,165)
23,491
-
(2)
1
51,675
(3,447)
(204)
4,131
12
171
52,338
(26,000)
(16,817)
(3,515)
-
-
-
-
-
-
-
-
(46,332)
(2,508)
89
(78)
(2,497)
Net (decrease) increase in cash and cash equivalents
(34,945)
3,509
Cash and cash equivalents, beginning of year
53,657
50,148
Cash and cash equivalents, end of year
$
18,712
$
53,657
See accompanying notes to consolidated financial statements.
Page | 4
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
1. Reporting entity
Andlauer Healthcare Group Inc. (“AHG”) was incorporated under the Ontario Business Corporations Act on
November 12, 2019 with its head office located in Woodbridge, Ontario. AHG’s subordinate voting shares are
listed on the Toronto Stock Exchange under the stock symbol “AND”. AHG specializes in third party logistics and
transportation solutions for the healthcare sector in Canada.
On December 4, 2019, AHG entered into an underwriting agreement and filed a long form prospectus for the
purpose of completing an initial public offering, which closed on December 11, 2019 (the ‘‘Closing’’). AHG raised
gross proceeds of $150,000 through the issuance of 10 million subordinate voting shares at a price of $15.00
per subordinate voting share. On December 16, 2019, a further 1.5 million subordinate voting shares were
issued at a price of $15.00 per subordinate voting share resulting in $22,500 of additional gross proceeds
pursuant to the exercise of an over-allotment option in the underwriting agreement. Transaction costs of
$15,273 were incurred in connection with the initial public offering, of which $14,321 have been offset against
the proceeds of the subordinate voting shares, and $952 have been expensed in the period.
Andlauer Management Group Inc. (“AMG”) holds all of the multiple voting shares of AHG and 75,000
subordinate voting shares, representing approximately 67% of the issued and outstanding shares and 89% of
the voting power attached to all of the shares. AMG is owned and controlled by Michael Andlauer, Chief
Executive Officer and a director of AHG.
2. Basis of presentation
a)
Statement of compliance
These consolidated financial statements have been prepared in accordance with International Financial
Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and using
the accounting policies described herein.
b) Basis of measurement
These consolidated financial statements were prepared on a going concern basis under the historical cost
method. Significant accounting policies are presented in note 3 to these consolidated financial statements
and have been consistently applied in each of the periods presented. These consolidated financial
statements were authorized for issue by the Board of Directors effective March 12, 2020.
These financial statements comprise the consolidated financial results of AHG and Associated Logistics
Solutions Inc., Credo Canada Systems Inc., 2186940 Ontario Inc. and their respective subsidiaries
(collectively, the “AHG Entities”) as at and for the year ended December 31, 2019 and the combined
financial results of the AHG Entities as at and for the year ended December 31, 2018 and up to the date of
the initial public offering (collectively the “Company”).
Common control transaction
In connection with a series of transactions that occurred prior to, and on, the date of Closing, AHG acquired
a 100% ownership interest in the AHG Entities in exchange for 25.1 million multiple voting shares valued at
$376,500, 1.0 million subordinate voting shares valued at $15,000 and a promissory note for $186,125
which was settled with the proceeds of the initial public offering and proceeds from the credit facilities
(note 11).
Page | 5
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
2. Basis of presentation (continued)
Common control transaction (continued)
AHG’s acquisition of the AHG Entities is a business combination involving entities under common control in
which all of the combining entities are ultimately controlled by AMG, both before and after the reorganization
transactions were completed. Business combinations involving entities under common control are outside the
scope of IFRS 3 Business Combinations. AHG accounted for this common control transaction using book value
accounting, based on the book values recognized in the financial statements of the underlying entities. This
election results in the financial statements being restated for periods prior to the date of obtaining common
control, to reflect the combination as if it had occurred from the beginning of the period that the entities were
under common control, regardless of the actual date the common control transaction closed.
(i) Total net parent investment
The comparative financial statements for 2018 have been prepared on a combined basis. Accordingly, it is
not meaningful to show share capital or provide an analysis of reserves. Therefore, amounts which reflect
the carrying value of investments in the combined entities are disclosed as “Total net parent investment”,
while carrying value of net assets attributable to shareholders other than the Company are presented as
“Non-controlling interests” (“NCI”). Since the Company was not an existing legal entity during 2018 and up
to December 10, 2019, the combined entities have no historical capital structure. Consequently, earnings
per share as required by IAS 33 Earnings per share has not been presented for 2018. The amounts reflected
in distributions and dividends in the consolidated statements of changes in equity refer to dividends or
distributions paid to the parent and dividends paid to NCI. Distributions and dividends of $112,016, net of
$9,379 of related income tax, were made to the parent in 2019.
(ii) Merger reserve
Pursuant to a share purchase agreement between AHG and its parent, and in connection with a corporate
reorganization immediately prior to the initial public offering, AHG acquired a 100% ownership interest in
the AHG Entities based on the value of consideration of $577,625. Total net parent investment as at
December 10, 2019 (immediately prior to the Closing) was $88,709. A merger reserve of $488,916 is
recorded to reflect the difference in carrying value of the net assets acquired and the consideration paid
since AHG and the AHG Entities were all related under the common control of AMG at the time of the
acquisition.
(iii) Employee trust
An employee trust was established at Closing, the beneficiaries of which will be executive officers and
employees of the Company. AHG made a non-interest bearing loan of $13,875 to the employee trust which
the employee trust used to acquire 925,000 subordinate voting shares from AMG. As the subordinate voting
shares are allocated and/or distributed to beneficiaries of the employee trust, contributions will be made
by the respective employer of any such beneficiary to the employee trust at $15.00 per subordinate voting
share and used by the employee trust to repay the non-interest bearing loan.
Page | 6
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
2. Basis of presentation (continued)
c) Basis of combination
(i) Business combinations
The Company measures goodwill as the fair value of the consideration transferred including the fair
value of liabilities resulting from contingent consideration arrangements, less the net recognized
amount of the identifiable assets acquired and liabilities assumed, all measured at fair value as of the
acquisition date. When the excess is negative, a bargain purchase gain is recognized immediately in
income or loss.
Transaction costs, other than those associated with the issue of debt or equity securities, that the
Company incurs in connection with a business combination are expensed as incurred.
(ii) Subsidiaries
The consolidated financial statements comprise the financial statements of the Company and its
subsidiaries. The Company controls an entity when it is exposed to, or has the right to, variable returns
from its involvement with the entity and has the ability to affect those through its power over the
entity. The financial statements of subsidiaries are included in the consolidated financial statements
from the date that control commences until the date that control ceases. The accounting policies of
subsidiaries are aligned with the policies adopted by the Company.
The Company’s wholly-owned subsidiaries include:
Entity
Incorporation Jurisdiction
2040637 Ontario Inc.
2186940 Ontario Inc.
2721275 Ontario Limited
Accuristix Healthcare Logistics Inc.
Accuristix Inc.
Accuristix
Associated Logistics Solutions Inc.
ATS Andlauer Transportation Services GP Inc.
ATS Andlauer Transportation Services LP
Concord Supply Chain Solutions Inc.1
Credo Systems Canada Inc.
Nova Pack Ltd.
MEDDS Winnipeg – A Medical Delivery Service Corporation
MEDDS Canada – A Medical Delivery Service Corporation1
Ontario
Ontario
Ontario
Ontario
Ontario
Ontario
Ontario
Canada
Manitoba
Delaware
Ontario
Ontario
Manitoba
Canada
1
Entity has been dormant throughout the entire reporting period.
(iii) Transactions eliminated on consolidation
Intercompany balances and transactions, and any unrealized income and expenses arising from
intercompany transactions, are eliminated in preparing the consolidated financial statements.
d)
Functional and presentation currency
These consolidated financial statements are presented in Canadian dollars, which is the Company’s
functional currency. All financial information presented in Canadian dollars has been rounded to the nearest
thousand.
Page | 7
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
2. Basis of presentation (continued)
e) Use of estimates and judgments
The preparation of the accompanying consolidated financial statements in conformity with IFRS requires
management to make judgments, estimates and assumptions about future events. These estimates and the
underlying assumptions affect the reported amounts of assets and liabilities, the disclosures about
contingent assets and liabilities, and the reported amounts of revenues and expenses. Such estimates
include the expected credit losses on accounts receivable, the useful life of long-lived assets, the Company’s
incremental borrowing rate, valuation of property, plant and equipment, valuation of goodwill and
intangible assets, the measurement of identified assets and liabilities acquired in business combinations,
share-based compensation arrangements, the provision for income taxes and other provisions and
contingencies. These estimates and assumptions are based on management’s best estimates and
judgments. Management evaluates its estimates and assumptions on an ongoing basis using historical
experience and other factors, including the current economic environment, which management believes to
be reasonable under the circumstances. Management adjusts such estimates and assumptions when facts
and circumstances dictate. Actual results could differ from these estimates. Changes in those estimates and
assumptions resulting from changes in the economic environment will be reflected in the consolidated
financial statements of future periods. Information about critical judgments, assumptions and estimation
uncertainties that have a significant risk of resulting in a material adjustment within the next financial year
are included in the following notes:
(cid:120)
(cid:120)
(cid:120)
(cid:120)
(cid:120)
(cid:120)
(cid:120)
Note 6 – Determining the expected credit losses related to trade accounts receivable;
Note 8 – Estimating the useful life of the Company’s property, plant and equipment and
determining estimates and assumptions related to impairment tests for long-lived assets;
Note 9 – Estimating the useful life of the Company’s intangible assets and determining estimates
and assumptions related to impairment tests for intangibles and goodwill;
Note 15 – Determining the valuation of share-based compensation arrangements;
Note 17 – Determining estimates and assumptions in measuring deferred tax assets and liabilities;
Note 18 – Estimating the Company’s incremental borrowing rate in connection with measuring lease
liabilities; and
Note 20 – Recognition and measurement of provisions and contingencies.
Page | 8
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
3.
Significant accounting policies
Foreign currency translation
Transactions in foreign currencies are translated to the respective functional currencies of each entity at
exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign
currencies are translated to the functional currency at the exchange rate in effect at the reporting date. The
foreign currency gain or loss on monetary items is the difference between amortized cost in the functional
currency at the beginning of the period, adjusted for effective interest and payments during the period, and the
amortized cost in foreign currency translated at the exchange rate at the end of the reporting period. Non-
monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated
at the rate in effect on the transaction date. Income and expense items denominated in foreign currency are
translated at the date of the transactions. Gains and losses are included in income or loss.
Revenue
Revenue is recognized upon transfer of control of promised products or services to customers in an amount that
reflects the consideration the Company expects to be entitled to receive in exchange for those products or
services.
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A
contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue
when, or as, the performance obligation is satisfied. The following is a description of the Company’s
performance obligations for the transportation and logistics reportable segments.
a)
Specialized Transportation
The Company’s transportation segment generates revenue from providing specialized ground
transportation, air freight forwarding and dedicated and last mile transportation services for its customers.
Certain additional services may be provided to customers as part of their transportation contracts, such as
temperature control and other incidental services. The transaction price is based on the consideration
specified in the customer’s contract. A contract exists when a customer under a transportation contract
submits a shipment document for the transport of goods from origin to destination. The performance
obligations within each contract are satisfied as the shipments move from origin to destination.
Transportation revenue is recognized proportionally as a shipment moves from origin to destination and
the related costs are recognized as incurred. Performance obligations are short-term, with transit days less
than one week. Generally, customers are billed upon shipment of the freight, and remit payment according
to approved payment terms.
b) Healthcare Logistics
The Company’s healthcare logistics segment generates revenue from providing supply chain services for its
customers, including logistics and distribution services and packaging solutions. The Company’s contracts
typically include a single performance obligation that is satisfied over time as customers simultaneously
receive and consume the benefits of the Company’s services. For this performance obligation, the Company
recognizes revenue at the invoiced amount, which is billed on a fixed price per unit of logistics activities
provided in the month, since this amount corresponds directly to the Company’s performance and the value
to the customer. In some cases, the Company’s contracts include other performance obligations related to
managing transportation and other customer services which are included in the logistics and distribution
product. These services are typically priced at their stand-alone selling prices and are recognized over time
on a proportionate and straight-line basis as the customer simultaneously receives and consumes the
benefits of the Company’s services.
Page | 9
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
3. Significant accounting policies (continued)
Revenue (continued)
b) Healthcare Logistics (continued)
In some cases, the contract will include optional services that are priced at their stand-alone selling prices.
These services are recognized as revenue when they are provided to the customer.
Customers are typically billed on a weekly basis for transactional transportation services, and on a monthly
basis for logistics and distribution services, and remit payment according to approved payment terms.
Payment terms may range under certain contracts, but are typically 30 days. The Company recognizes
unbilled revenue for transportation service revenue that has been recognized, but is not yet billed. The
Company will also recognize deferred revenue when customers are billed in advance for transportation and
logistics and distribution services.
Property, plant and equipment
Property, plant and equipment is accounted for at cost less accumulated depreciation and accumulated
impairment losses.
Cost includes expenditures that are directly attributable to the acquisition of the asset, the costs of dismantling
and removing the assets and restoring the site on which they are located and borrowing costs on qualifying
assets.
When parts of an item of property, plant and equipment have different useful lives, they are accounted for as
separate items (major components) of property, plant and equipment.
Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the
proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized in net
income or loss.
Depreciation is based on the cost of an asset less its residual value and is recognized in income or loss over the
estimated useful life of each component of an item of property, plant and equipment. Leased assets are
depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the
Company will obtain ownership by the end of the lease term.
Depreciation is computed on either a declining balance basis or a straight-line basis over the estimated useful
lives of the assets as follows:
Asset
Facilities
Furniture and fixtures
Leasehold improvements
Logistics and transportation equipment
Amortization Method
Straight-line over the term of the lease
20-30% declining balance
5-15 year straight-line subject to the shorter of remaining
lease term or useful life
20-30% declining balance, except for storage vaults – which
are amortized straight line over 40 years
Property, plant and equipment acquired or constructed during the year but not placed into use during the year
are not amortized until put into use.
Page | 10
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
3. Significant accounting policies (continued)
Goodwill and intangible assets
Recognition and measurement
Goodwill arising on the acquisition of subsidiaries is measured at cost less accumulated impairment losses.
Intangible assets consist of customer relationships and internally generated software.
For internally generated software, expenditure on research activities is recognized in profit or loss as incurred.
Development expenditure is capitalized only if the expenditure can be measured reliably, the product or process
is technically and commercially feasible, future economic benefits are probable and the Company intends to
and has sufficient resources to complete development and to use or sell the asset. Otherwise, it is recognized
in profit or loss as incurred. Subsequent to initial recognition, development expenditure is measured at cost less
accumulated amortization and any accumulated impairment losses.
Customer relationships that are acquired by the Company and have finite useful lives are measured at cost less
accumulated amortization and any accumulated impairment losses.
Amortization
Goodwill is not amortized.
Internally generated software is amortized on a straight-line basis over 10 years. Internally generated software
acquired or constructed during the year but not placed into use during the year is not amortized until placed
into use.
Customer relationships are amortized on a straight-line basis over their estimated useful lives of between 5 and
10 years.
Impairment
The carrying amounts of the Company’s non-financial assets other than inventoried supplies and deferred tax
assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any
such indication exists, then the asset’s recoverable amount is estimated.
For goodwill, the recoverable amount is estimated on December 31 of each year as part of the annual
impairment test. For the purpose of impairment testing, assets that cannot be tested individually are grouped
together into the smallest group of assets that generates cash inflows from continuing use that are largely
independent of the cash inflows of other assets or groups of assets (the “cash-generating unit”, or “CGU”).
For the purposes of goodwill impairment testing, goodwill acquired in a business combination is allocated to the
group of CGUs (usually an operating segment of the Company), that is expected to benefit from the synergies
of the combination. This allocation is subject to an operating segment ceiling test and reflects the lowest level
at which that goodwill is monitored for internal reporting purposes. The recoverable amount of an asset or CGU
is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future
cash flows are discounted to their present value using a pre-tax discount rate that reflects current market
assessments of the time value of money and the risks specific to the asset or group of assets.
An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable
amount. Impairment losses recognized in respect of CGUs are allocated first to reduce the carrying amount of
any goodwill allocated to the units, if any, and then to reduce the carrying amounts of the other assets in the
unit (group of units) on a prorated basis.
Page | 11
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
3. Significant accounting policies (continued)
Goodwill and intangible assets (continued)
Impairment (continued)
An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses
recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased
or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine
the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount
does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if
no impairment loss had been recognized. Impairment losses and impairment reversals are recognized in income
or loss.
Leases
At inception of a contract, the Company assesses whether a contract is, or contains a lease. A contract is, or
contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in
exchange for consideration. To assess whether a contract conveys the right to control the use of an identified
asset, the Company assesses whether:
(cid:120)
(cid:120)
(cid:120)
The contract involves the use of an identified asset – this may be specified explicitly or implicitly, and should
be physically distinct or represents substantially all the capacity of a physically distinct asset. If the supplier
has a substantive substitution right, then the asset is not identified;
The Company has the right to obtain substantially all of the economic benefits from use of the asset
throughout the period of use; and
The Company has the right to direct the use of the asset. The Company has the right when it has the
decision-making rights that are most relevant to changing how and for what purpose the asset is used. In
rare cases where the decision about how and for what purpose the asset is used is predetermined, the
Company has the right to direct the use of the asset if either:
-
-
the Company has the right to operate the asset; or
the Company designed the asset in a way that predetermines how and for what purpose it will be
used.
At inception or on reassessment of a contract that contains a lease component, the Company allocates the
consideration in the contract to each lease component on the basis of their relative stand-alone prices. For the
leases of land and buildings in which it is a lessee, the Company has elected to account for the lease and non-
lease components separately.
a)
For arrangements in which the Company is a lessee
The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the lease commencement date.
The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted
for any lease payments made at or before the commencement date, plus any initial direct costs incurred
and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset
or the site on which it is located, less any lease incentives received.
The ROU asset is subsequently depreciated using the straight-line method from the commencement date
to the earlier of the end of the useful life of the ROU asset or the end of the lease term. The estimated
useful lives of ROU assets are determined by the estimated lease term. In addition, the ROU asset is
periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease
liability.
Page | 12
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
3. Significant accounting policies (continued)
Leases (continued)
a)
For arrangements in which the Company is a lessee (continued)
The lease liability is initially measured at the present value of the lease payments that are not paid at the
commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be
readily determined, the Company’s incremental borrowing rate. Generally, the Company uses its
incremental borrowing rate as the discount rate.
Lease payments included in the measurement of the lease liability comprise the following:
(cid:120)
(cid:120)
(cid:120)
(cid:120)
fixed payments, including in-substance fixed payments;
variable lease payments that depend on an index or a rate, initially measured using the index or
rate as at the commencement date;
amounts expected to be payable under a residual value guarantee; and
the exercise price under a purchase option that the Company is reasonably certain to exercise,
lease payments in an optional renewal period if the Company is reasonably certain to exercise an
extension option, and penalties for early termination of a lease unless the Company is reasonably
certain not to terminate early.
The lease liability is measured at amortized cost using the effective interest method. It is re-measured when
there is a change in future lease payments arising from a change in an index or rate, if there is a change in
the Company’s estimate of the amount expected to be payable under a residual value guarantee, or if the
Company changes its assessment of whether it will exercise a purchase, extension or termination option.
When the lease liability is re-measured in this way, a corresponding adjustment is made to the carrying
amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use
asset has been reduced to zero.
b)
Short-term leases and leases of low-value assets
The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases of
machinery that have a lease term of 12 months or less and leases of low-value assets, including IT
equipment. The Company recognizes the lease payments associated with these leases as an expense on a
straight-line basis over the lease term.
c)
For arrangements in which the Company is a lessor
When the Company acts as a lessor, it determines at lease inception whether each lease is a finance lease
or an operating lease.
To classify each lease, the Company makes an overall assessment of whether the lease transfers
substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case,
then the lease is a finance lease; if not, then it is an operating lease. As part of this assessment, the Company
considers certain indicators such as whether the lease is for the major part of the economic life of the asset.
If an arrangement contains lease and non-lease components, the Company applies IFRS 15 to allocate the
consideration in the contract.
The Company recognizes lease payments received under operating leases as income on a straight line basis
over the lease term as part of ‘other income’.
Page | 13
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
3. Significant accounting policies (continued)
Income taxes
Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in income
or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in
other comprehensive income.
Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates
enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous
years.
Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not
recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction
that is not a business combination and that affects neither accounting nor taxable income or loss, and
differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable
that they will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable
temporary differences arising on the initial recognition of goodwill. Deferred tax is measured at the tax rates
that are expected to be applied to temporary differences when they reverse, based on the laws that have been
enacted or substantively enacted at the reporting date. Deferred tax assets and liabilities are offset if there is a
legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the
same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax
liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.
A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to
the extent that it is probable that future taxable income will be available against which they can be utilized.
Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer
probable that the related tax benefit will be realized.
Financial instruments
Financial assets
Accounts receivable are initially recognized when they are originated. All other financial assets and financial
liabilities are initially recognized when the Company becomes a party to the contractual provisions of the
instrument.
A financial asset (unless it is an account receivable without a significant financing component) or financial
liability is initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL),
transaction costs that are directly attributable to its acquisition or issue. An account receivable without a
significant financing component is initially measured at the transaction price.
The Company’s financial assets are comprised of cash and cash equivalents, accounts receivable, due from
related parties, and long-term deposits. On initial recognition, the Company classifies these financial assets as
measured at amortized cost, when both of the following conditions are met:
(cid:120)
(cid:120)
it is held within a business model whose objective is to hold assets to collect contractual cash flows;
and
its contractual terms give rise on specified dates to cash flows that are solely payments of principal and
interest on the principal amount outstanding.
Page | 14
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
3. Significant accounting policies (continued)
Financial instruments (continued)
Financial assets (continued)
These financial assets are subsequently measured at amortized cost using the effective interest method. The
amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and
impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss.
Impairment of financial assets
Financial assets are assessed for indicators of impairment at the end of each reporting period. Financial assets
are considered to be impaired when there is objective evidence that, as a result of one or more events that
occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment
have been decreased.
For accounts receivables, the Company applies a simplified approach in calculating expected credit losses
(“ECLs”). Therefore the Company does not track changes in credit risk, but instead recognizes a loss allowance
based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on
its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the
economic environment.
When an account receivable is considered uncollectible, it is written off against the allowance account.
Subsequent recoveries of amounts previously written off are offset against the allowance account. Changes in
the carrying amount of the allowance account are recognized in profit or loss.
Financial liabilities are classified at amortized cost
The Company’s financial liabilities are measured at amortized cost using the effective interest method. Interest
expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition
is also recognized in profit or loss.
Transaction costs
Transaction costs that are incremental and directly attributable to the acquisition or issue of a financial asset of
financial liability are recorded as follows:
(cid:120)
(cid:120)
(cid:120)
Financial assets or financial liabilities at fair value through profit and loss – expensed to net income as
incurred;
Financial assets or liabilities recorded at amortized cost – included in the carrying value of the financial
asset or financial liability and amortized over the expected life of the financial instrument using the
effective interest method; and
Equity instruments recorded at fair value through other comprehensive income – included in the initial
cost of the underlying asset.
Page | 15
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
3. Significant accounting policies (continued)
Inventories
Inventories, which consist of repair parts, materials and supplies, are carried at the lower of cost and net
realizable value. Cost is determined on a first-in, first-out basis and includes all costs of purchase and any other
costs incurred in bringing the inventories to their present location and condition. Net realizable value is the
estimated selling price in the ordinary course of business, less applicable variable selling expenses.
Provisions
A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation
that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle
the obligation. If the effect of the time value of money is material, provisions are determined by discounting the
expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money
and the risks specific to the liability. Where discounting is used, the unwinding of the discount is recognized as
finance cost.
Segmented reporting
The Company is organized into two reportable segments: Specialized Transportation and Healthcare Logistics.
In the Specialized Transportation segment, the Company provides specialized temperature controlled services
to healthcare customers. The Company’s transportation products include: ground transportation (comprising
less-than-truckload and courier services), air freight forwarding, and dedicated and last mile delivery.
In the Healthcare Logistics segment, the Company provides contract logistics services for customers, including
logistics and distribution (comprising warehousing and inventory management, order fulfillment, reverse
logistics, and transportation management), and packaging (comprising reusable thermal packaging solutions
and trade customization services).
Certain of the Company’s operating units provide services to other Company operating units outside of their
reportable segment. Billings for such services are based on negotiated rates, which approximates fair value, and
are reflected as revenues of the billing segment. These rates are adjusted from time to time based on market
conditions. Such intersegment revenues and expenses are eliminated in the Company’s consolidated results.
The Company’s chief executive officer is the Chief Operating Decision Maker (“CODM”) for the Company. The
CODM regularly reviews financial information at the reporting segment level in order to make decisions about
resources to be allocated to the segments and to assess their performance. Segment results that are reported
to the CODM include items directly attributable to a segment, as well as those that can be allocated on a
reasonable basis. The Company evaluates performance based on the various financial measures of its two
reporting segments.
Page | 16
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
3. Significant accounting policies (continued)
Share-based compensation
The Company has an omnibus stock option plan and records all stock-based payments, including grants of
employee stock options, at their respective fair values. The fair value of stock options granted to employees and
directors is estimated at the date of grant using the Black Scholes option pricing model. The Company recognizes
share-based compensation expense over the vesting period, over the life of the tranche of shares being
considered. The Company also estimates forfeitures at the time of grant and revises its estimate, if necessary,
in subsequent periods if actual forfeitures differ from these estimates. Any consideration paid by employees on
exercising stock options and the corresponding portion previously credited to additional paid-in capital are
credited to share capital. The Company’s stock option plan is equity-settled.
The Black-Scholes option pricing model used by the Company to calculate option values was developed to
estimate the fair value. This model also requires assumptions, including expected option life, volatility, risk-free
interest rate and dividend yield, which greatly affect the calculated values.
Expected option life is determined using the time-to-vest-plus-historical-calculation-from-vest-date method
that derives the expected life based on a combination of each tranche’s time to vest plus the actual or expected
life of an award based on the past activity or remaining time to expiry on outstanding awards. Expected
forfeiture is derived from historical patterns. Expected volatility is determined using comparable companies for
which the information is publicly available, adjusted for factors such as industry, stage of life cycle, size and
financial leverage. The risk-free interest rate is determined based on the rate at the time of grant and
cancellation for zero-coupon Canadian government securities with a remaining term equal to the expected life
of the option. Dividend yield is based on the stock option’s exercise price and expected annual dividend rate at
the time of grant.
Forthcoming standards
Certain new accounting standards and interpretations have been published that are not mandatory for
December 31, 2019 reporting periods and have not been early adopted by the Company. The Company’s
assessment of the impact of these new standards and interpretations is set out below:
(a) Amendments to IFRS 3 Business Combinations – Change in definition of business
In October 2018, the IASB issued amendments to IFRS 3 Business Combinations that seek to clarify whether
a transaction results in an asset or a business acquisition.
The amendments include an election to use a concentration test. This is a simplified assessment that results
in an asset acquisition if substantially all of the fair value of the gross assets is concentrated in a single
identifiable asset or a group of similar identifiable assets. If a preparer chooses not to apply the
concentration test, or the test is failed, then the assessment focuses on the existence of a substantive
process.
The amendment applies to businesses acquired in annual reporting periods beginning on or after January
1, 2020. Earlier application is permitted. The application of this amendment is not expected to have a
material impact on the consolidated financial statements.
(b) Amendments to IAS 1 and IAS 8 - Definition of ‘Material’
In October 2018, the IASB refined its definition of material to make it easier to understand. In the
amendment, IASB promoted the concept of ‘obscuring’ to the definition, alongside the existing references
to ‘omitting’ and ‘misstating’. Additionally, the IASB increased the threshold of ‘could influence’ to ‘could
reasonably be expected to influence’. The amendments are effective from January 1, 2020 but may be
applied earlier. The application of this amendment is not expected to have a material impact on the
consolidated financial statements.
Page | 17
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
4. Segment reporting
The Company is organized into two operating segments, which it also considers to be reportable segments:
Specialized Transportation and Healthcare Logistics. The operating segments are managed independently as
they require different technology and capital resources. For each of the operating segments, the Company’s
CODM reviews internal management reports, evaluating the metrics as summarized in the tables below.
The Company evaluates performance based on the various financial measures of its two operating segments.
Performance is measured based on segment income or loss before tax. This measure is included in the internal
management reports that are reviewed by the Company’s CEO and refers to “Income before income taxes” in
the consolidated statements of income and comprehensive income. Segment income or loss before tax is used
to measure performance as management believes that such information is the most relevant in evaluating the
results of certain segments relative to other entities that operate within the same industries. The following table
identifies selected financial data as at December 31, 2019 and 2018 and for the years then ended:
Specialized
Transportation
Healthcare
Logistics
Corporate
Eliminations
Total
$
$
As at December 31, 2019 and
for the year then ended
Revenue
Segment income before tax
Interest income
Interest expense
Depreciation and amortization
Segment net income
Segment total assets
Acquisition of ROU assets
Capital expenditures
Segment total liabilities
As at December 31, 2018 and
for the year then ended
Revenue
Segment income before tax
Interest income
Interest expense
Depreciation and amortization
Segment net income
Segment total assets
Acquisition of ROU assets
Capital expenditures
Segment total liabilities
$
$
205,385
33,995
901
(1,796)
16,137
24,861
125,673
26,311
3,744
80,287
193,720
29,739
1,106
(1,173)
13,768
21,578
187,255
18,643
1,558
57,579
$
$
109,618
10,770
103
(1,639)
9,569
7,900
91,837
2,542
2,232
46,750
106,430
8,977
4
(2,106)
9,723
6,607
93,235
196
1,046
53,183
-
(2,416)
-
(68)
-
(2,416)
592,350
-
-
43,693
-
-
-
-
-
-
-
-
-
-
$
$
$
$
(25,015)
-
-
-
-
(572)
(596,865)
-
(41)
(19,240)
(23,140)
-
(231)
231
-
(1,462)
(3,913)
-
(96)
(3,913)
289,988
42,349
1,004
(3,503)
25,706
29,773
212,995
28,853
5,935
151,490
277,010
38,716
879
(3,048)
23,491
26,723
276,577
18,839
2,508
106,849
The Company’s Healthcare Logistics segment purchases transportation services from
its Specialized
Transportation segment. Fees for these services are based on negotiated rates, which approximate fair value,
and are reflected as revenues of the Specialized Transportation segment. Rates are adjusted from time to time
based on market conditions. Intersegment revenues and expenses and related intersegment payables and
receivables are eliminated in the Company’s consolidated results.
Page | 18
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
4. Segment reporting (continued)
An intersegment loan from the Specialized Transportation segment to the Healthcare Logistics segment was
repaid during 2018. The intersegment loan balance and related interest income and expense are eliminated
from the Company’s consolidated results.
The Company does not have any customers that individually represent more than 10% of revenue.
5. Cash and cash equivalents
Bank balances
Deposits
Cash and cash equivalents
December 31,
2019
December 31,
2018
$
$
18,712
-
18,712
$
$
48,502
5,155
53,657
Cash and cash equivalents includes a $nil (2018 - $5,155) short-term deposit with a six-month term that is held
by the Company. The deposit bears an annual interest rate of 2.50% and was redeemed on June 6, 2019. Accrued
interest at December 31, 2019 is $nil (2018 - $7).
6. Accounts receivable
Trade receivables
Trade receivables due from related parties (note 21)
Impairment loss
Accounts receivable
7.
Inventories
Inventories consist of:
Packaging inventory
Thermal packaging products and parts
Inventories
December 31,
2019
December 31,
2018
$
$
50,769
441
(150)
51,060
$
$
48,424
383
(377)
48,430
December 31,
2019
December 31,
2018
$
$
840
231
1,071
$
$
943
423
1,366
In 2019, the Company purchased a total of $5,710 in inventory (2018 - $6,515) and $6,005 was recognized as an
expense (2018 - $6,311) during the year and included in direct operating expenses.
Page | 19
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
8. Property, plant and equipment
Reconciliation of the net carrying amounts for each class of property, plant and equipment is summarized below:
Facilities1
Furniture and
fixtures
Leasehold
improvements
Logistics and
transportation
equipment1
Total
Cost
Balance at December 31, 2017
$
71,485
$
7,515
$
13,501
$
57,978
$ 150,479
Additions
Dispositions
Balance at December 31, 2018
Additions
Dispositions
7,623
-
79,108
17,708
-
2
-
7,517
290
-
1,201
-
14,702
2,033
(330)
12,521
(175)
70,324
14,758
-
21,347
(175)
171,651
34,789
(330)
Balance at December 31, 2019
$
96,816
$
7,807
$
16,405
$
85,082
$ 206,110
Accumulated depreciation
Balance at December 31, 2017
Depreciation for the year
Dispositions
Balance at December 31, 2018
Depreciation for the year
Dispositions
19,614
9,860
-
29,474
11,057
-
5,191
423
-
5,614
379
-
4,470
1,378
-
5,848
1,652
(223)
29,789
9,164
(85)
38,868
10,115
-
59,064
20,825
(85)
79,804
23,203
(223)
Balance at December 31, 2019
$
40,531
$
5,993
$
7,277
$
48,983
$ 102,784
Net carrying amounts
At December 31, 2018
At December 31, 2019
$
$
49,634
56,285
$
$
1,903
1,814
$
$
8,854
9,128
$
$
31,456
36,099
$
91,847
$ 103,326
1 Facilities and certain logistics and transportation equipment assets are ROU assets, capitalized in accordance with IFRS
16. Refer to note 18.
Page | 20
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
9. Goodwill and intangible assets
Goodwill
Customer
relationships
Software
Proprietary
technology
Total
Cost
Balance at December 31, 2017
$
19,720 $
22,545 $
5,245 $
1,156 $
48,666
Additions
-
-
Balance at December 31, 2018
19,720
22,545
Additions
-
-
78
5,323
230
-
1,156
-
78
48,744
230
Balance at December 31, 2019
$
19,720 $
22,545 $
5,553 $
1,156 $
48,974
Accumulated amortization
Balance at December 31, 2017
$
Amortization for the year
Balance at December 31, 2018
Amortization for the year
Balance at December 31, 2019
$
-
-
-
-
-
$
18,366 $
2,862 $
1,156 $
22,384
2,180
20,546
1,999
486
3,348
504
-
1,156
-
2,666
25,050
2,503
$
22,545 $
3,852 $
1,156 $
27,553
Net carrying amounts
At December 31, 2018
At December 31, 2019
$
$
19,720 $
19,720 $
1,999 $
1,975 $
-
$
1,701 $
-
-
$
$
23,694
21,421
The Company performs annual goodwill impairment testing for the Healthcare Logistics segment. The Company
assesses goodwill at the operating segment level, which is the lowest level within the Company at which the
goodwill is monitored for internal management purposes. The results of the annual impairment testing
determined that the recoverable amount of the Healthcare Logistics operating segment exceeded the respective
carrying amount. The recoverable amount of the Healthcare Logistics operating segment was determined using
the value in use approach. The value in use methodology is based on discounted future cash flows. Management
believes that the discounted future cash flows method is appropriate as it allows more precise valuation of
specific future cash flows. Therefore, the Company has determined that no impairment has arisen in connection
with the CGU that gave rise to goodwill through the business combination. Accordingly, no impairment loss has
been recognized in each of the years ended December 31, 2019 and 2018.
The majority of the customer relationships and proprietary technology reflects intangible assets that arose from
a business combination in 2008 of the Specialized Transportation segment and the subsequent disposal of a
portion of those operations in 2009. As at November 1, 2009, customer relationships intangibles of $21,801
were recognized with straight-line amortization over 10 years.
The Company performs an assessment for indicators of impairment for customer relationships and software at
each reporting period. If an indicator of impairment exists, the Company would perform an impairment test to
determine the recoverable amount. No such indicators of impairment were identified at any of the reporting
periods covered by these financial statements.
Page | 21
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
10. Accounts payable and accrued liabilities
Trade payables and accrued liabilities
Trade payables due to related parties (note 21)
Deferred revenue (note 16)
11. Credit facilities
Revolving credit facility
Term facility
Less: financing costs
Recorded in the consolidated balance sheets as follows:
Revolving credit facility
Term facility
The movement in credit facilities from December 31, 2018 is as follows:
Balance at December 31, 2018
Changes from financing cash flows
Issuance of borrowings – revolving credit facility
Issuance of borrowings – term facility
Less: financing costs
Repayment of revolving credit facility
Non-cash movements
Adjustment to capitalized financing costs
December 31,
2019
December 31,
2018
$
$
22,047
2,016
879
24,942
$
$
25,782
577
737
27,096
December 31,
2019
December 31,
2018
$
$
3,929
25,000
28,929
(445)
28,484
$
$
-
-
-
-
-
December 31,
2019
December 31,
2018
$
$
3,929
24,555
28,484
$
$
-
-
-
Credit facilities
$
-
25,000
25,000
50,000
(470)
49,530
(21,071)
28,459
25
Balance at December 31, 2019
$
28,484
Page | 22
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
11. Credit facilities (continued)
On December 11, 2019 the Company entered into credit facilities with affiliates of RBC and CIBC at Closing of
the initial public offering. The credit facilities comprise a revolving credit facility in the aggregate principal
amount of $75,000 and a term facility in the aggregate principal amount of $25,000. The credit facilities are
available to be drawn in Canadian dollars by way of prime rate loans, bankers’ acceptances and letters of credit,
and in U.S. dollars by way of base rate loans, LIBOR based loans and letters of credit, in each case, plus the
applicable margin in effect from time to time. At December 31, 2019, both the revolving credit facility and the
term facility comprise prime rate loans at an interest rate of 4.4%.
The credit facilities are guaranteed by each of the Company’s material subsidiaries and are secured by (i) a first
priority lien over all personal property of the Company, subject to certain exclusions and permitted liens, (ii)
charges over certain material leased real property interests, and (iii) a first ranking pledge of 100% of the
securities of any subsidiary owned by the Company.
The credit facilities are subject to customary negative covenants and include financial covenants requiring the
Company to maintain at all times a maximum net leverage ratio and a minimum interest coverage ratio, tested
on a quarterly basis. At December 31, 2019, the Company is in compliance with all of its covenants under the
credit facilities.
The credit facilities will mature and be due and payable on December 11, 2023.
Amounts recognized in the consolidated statements of income and comprehensive income in connection with
interest expense for the credit facilities in 2019 was $68 (2018 – $nil).
12. Financial instruments and financial risk management
Accounting classifications and fair values
The Company's financial instruments consist of cash and cash equivalents, accounts receivable, deposits, and
accounts payable and accrued liabilities. The Company believes that the carrying amount of each of these
items is a reasonable approximation of fair value.
Financial risk factors
The Company, through its financial assets and liabilities, has exposure to the following risks from its use of
financial instruments: credit risk, liquidity risk, interest rate risk, and currency risk. Senior management
monitors risk levels and reviews risk management activities as they determine to be necessary.
Credit risk
The Company is exposed to credit risk in the event of non-performance by counterparties in connection with
its financial assets, namely cash and cash equivalents, accounts receivable and long-term deposits. The
Company does not typically obtain collateral or other security to support the accounts receivable subject to
credit risk but mitigates this risk by performing credit check procedures for new customers and monitoring
credit limits for existing customers. Thereby, the Company deals only with what management believes to be
financially sound counterparties and, accordingly, does not anticipate significant loss for non-performance.
The maximum exposure to credit risk for cash and cash equivalents, accounts receivable and long-term
deposits approximate the amount recorded on the consolidated balance sheets.
Page | 23
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
12. Financial instruments and financial risk management (continued)
Credit risk (continued)
Accounts receivable aging is set out below:
Current (not past due)
0-30 days past due
31-60 days past due
More than 61 days past due
Gross
Unbilled revenue (note 16)
Impairment loss
Accounts receivable, net
Liquidity risk
December 31,
2019
December 31,
2018
$
$
31,198
12,863
3,567
1,306
48,934
2,276
(150)
51,060
$
$
25,630
15,288
6,047
341
47,306
1,501
(377)
48,430
Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with
its financial liabilities that are settled by delivering cash or another financial asset. The Company’s approach to
managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when
they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking
damage to the Company’s reputation.
The Company’s exposure to liquidity risk is dependent on the collection of accounts receivable, or raising of
funds to meet commitments and sustain operations. The Company controls liquidity risk by management of
working capital, cash flows and the availability of borrowing facilities.
As of December 31, 2019, $3,929 (2018 - $nil) has been drawn on the $75,000 revolving credit facility, and
$25,000 (2018 - $nil) has been drawn on the $25,000 term facility. There is no amortization of the term facility.
The credit facilities are repayable in full on December 31, 2023.
The Company’s accounts payable and accrued liabilities are due and payable in the short-term.
Interest rate risk
The Company has a revolving and term credit facilities that bear interest at a floating rate subject to
fluctuations in the bank prime rate. Changes in the bank prime lending rate can cause fluctuations in interest
payments and cash flows. The Company does not use derivative financial instruments to mitigate the effect of
this risk. The facilities under this agreement bear interest at prime plus 0.45% per annum. At December 31,
2019, the interest rate was 4.4%.
Due to timing at which the Company entered into the credit facilities in relation to its year end, there has been
no exposure to significant interest rate fluctuations.
Page | 24
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
12. Financial instruments and financial risk management (continued)
Currency risk
The Company enters into foreign currency purchase and sale transactions and has assets and liabilities that
are denominated in foreign currencies and thus are exposed to the financial risk of earnings fluctuations arising
from changes in foreign exchange rates and the degree of volatility of these rates. The Company does not
currently use derivative instruments to reduce its exposure to foreign currency risk.
At year-end, the Company has the following US dollar foreign currency denominated balances:
Currency risk
Cash
Accounts receivable
Accounts payable and accrued liabilities
13. Share capital
December 31,
2019
December 31,
2018
$
$
544
85
55
491
108
732
The Company is authorized to issue an unlimited number of subordinate voting shares, an unlimited number
of multiple voting shares, and an unlimited number of preferred shares, issuable in series. The subordinate
voting shares and multiple voting shares rank pari passu with respect to the payment of dividends, return of
capital and distribution of assets in the event of liquidation, dissolution, or wind-up. Holders of multiple voting
shares are entitled to four votes per multiple voting share, and holders of subordinate voting shares are
entitled to one vote per subordinate voting share on all matters upon which holders of shares are entitled to
vote.
All of the multiple voting shares and 75 thousand subordinate voting shares are owned by the Company’s
parent, AMG. The following table summarizes the number of common shares issued (note 1):
Number of common shares (in thousands)
Share capital (in thousands of dollars)
Multiple
voting
common
shares
Subordinate
voting
common
shares
Total
common
shares
Multiple
voting
common
shares
Subordinate
voting
common
shares
Total share
capital
-
-
-
$
-
$
-
$
-
25,100
1,000
26,100
376,500
15,000
391,500
-
-
-
10,000
10,000
1,500
-
1,500
-
-
-
-
150,000
150,000
22,500
(14,321)
22,500
(14,321)
Balance at November 12, 2019
Shares issued in connection with the
acquisition of the AHG Entities
Shares issued in connection with the
initial public offering
Share issued in connection with the
over-allotment option
Transaction costs
Balance at December 31, 2019
25,100
12,500
37,600
$ 376,500
$ 173,179
$ 549,679
Page | 25
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
14. Earnings per share
Basic earnings per share
The basic earnings per share and the weighted average number of common shares outstanding have been
calculated as follows:
(in thousands of dollars and number of shares)
Net income attributable to the common shareholders of the Company
Weighted average number of common shares
Earnings per share – basic
December 31,
2019
$
29,773
37,600
$
0.79
Diluted earnings per share
The basic earnings per share and the weighted average number of common shares outstanding after adjustment
for the effects of all dilutive common shares have been calculated as follows:
(in thousands of dollars and number of shares)
Net income attributable to the common shareholders of the Company
Weighted average number of common shares
Dilutive effect:
Stock options
Weighted average number of diluted common shares
Earnings per share – diluted
December 31,
2019
$
29,773
37,600
169
37,769
$
0.79
Page | 26
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
15. Share-based payment arrangements
Stock option plan (equity-settled)
The Company offers a stock option plan for the benefit of certain of its employees. Each stock option entitles its
holder to receive one subordinate voting common share upon exercise. The exercise price payable for each
option is determined by the Board of Directors at the date of grant. The options vest in equal installments over
four years and the expense is recognized following the accelerated method as each installment is fair valued
separately and recorded over the respective vesting periods.
On December 11, 2019 the Board of Directors approved a grant of 1,650 thousand options. Of the options
outstanding at December 31, 2019, a total of 700 thousand are held by non-executive directors; 400 thousand
are held by executive officers; with the remaining 550 thousand held by key management personnel.
The fair value of the stock options granted was estimated using the Black-Scholes option pricing model using
the following weighted average assumptions:
Exercise price
Average expected option life
Risk-free interest rate
Expected stock price volatility
Average dividend yield
Weighted average fair value per option of options granted
December 11,
2019
$
$
15.00
7 years
1.59%
24.77%
1.33%
3.60
In connection with the initial public offering, all non-executive directors were awarded 50 thousand options
each which vested immediately. A total of 350 thousand options are exercisable at December 31, 2019.
The table below summarizes the changes in the outstanding stock options:
(in thousands of options and in dollars)
Balance at November 12, 2019
Granted
Exercised
Forfeited
Balance at December 31, 2019
December 31, 2019
Number of
options
-
1,650
-
-
1,650
$
Weighted
average
exercise price
-
15.00
-
-
15.00
Options exercisable at December 31, 2019
350
$
15.00
In 2019, the initial year in which stock options were granted, the Company recognized a compensation expense
of $1,394 with a corresponding increase to contributed surplus.
Page | 27
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
16. Revenue
A. Revenue streams
The Company generates revenue primarily from the provision of supply chain transportation and logistics
services to its customers. The Company’s contracts are typically satisfied over a short period of time.
Consequently, the Company applies the practical expedient and does not disclose information related to its
remaining performance obligations.
B. Disaggregation of revenue from contracts with customers
In the following table, revenue from contracts with customers is disaggregated by major products and
service lines. The table also includes a reconciliation of the disaggregated revenue with the Company’s
reportable segments (note 4).
Major products/service lines
Logistics and distribution
Packaging
Healthcare Logistics segment
Ground transportation
Air freight forwarding
Dedicated and last mile delivery
Intersegment revenue
Specialized Transportation segment
Total revenue
C. Unbilled and deferred revenue
December 31,
2019
December 31,
2018
$
$
88,311
21,307
109,618
169,040
19,656
16,689
(25,015)
180,370
289,988
$
$
85,125
21,305
106,430
160,489
19,332
13,899
(23,140)
170,580
277,010
At the end of a reporting period, the Company recognizes unbilled revenue where revenue has been
recognized but for which an invoice has not yet been issued. These amounts are disclosed in note 12. The
Company’s unbilled revenue has increased from 2018 to 2019 throughout the period consistently with the
annual growth in revenue.
The Company bills customers for transportation services based on the pick-up date. When shipments
remain in transit at the end of a period, the Company defers revenue until the shipments are delivered. The
Company does not regularly bill customers in advance for logistics and distribution services. Consequently,
fluctuations in deferred revenue will occur year over year and will depend on specifically negotiated
payment terms resulting from customer billing requests or concerns related to credit risk. To date, the
changes in deferred revenue (note 10) have been largely insignificant. Revenue recognized in 2019 of $647
(2018 – $681) was included in the opening deferred revenue balance at the beginning of the year.
Page | 28
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
17. Income taxes
A. Amounts recognized in profit or loss
Current income tax expense:
Current taxes on income for the reporting period
Current taxes referring to previous periods and
other adjustments
Deferred income tax expense (recovery):
Origination and reversal of temporary differences
Impact of change in tax rates of subsidiaries
Deferred taxes referring to previous periods and
other adjustments
Income tax expense reported to the statements
of income and comprehensive income
December 31,
2019
December 31,
2018
$
11,718
$
10,641
$
(77)
11,641
(108)
10,533
$
361
(21)
23
363
(134)
4
128
(2)
$
12,004
$
10,531
Total cash outflow for actual taxes paid in 2019 was $12,331 (2018 – $10,100).
B. Reconciliation of effective tax rate
Income before income taxes
Consolidated Canadian federal and provincial
income tax rate
(26.5% consolidated rate)
Income tax expense based on statutory rate
Increase (decrease) in income taxes resulting
from non-taxable items or adjustments of prior
year taxes:
Permanent differences
Impact of varying statutory tax rates of subsidiaries
Unrecognized tax losses
Taxes relating to previous periods and other
adjustments
Total income tax expense
December 31,
2019
December 31,
2018
$
42,349
$
38,716
26.50%
11,222
$
26.50%
10,260
$
427
122
271
61
183
-
(38)
12,004
$
27
10,531
$
Page | 29
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
17. Income taxes (continued)
C. Deferred taxes
Deferred tax assets
Deferred tax liabilities
Net deferred tax (liability) asset
D. Movement in deferred tax balances
December 31,
2019
December 31,
2018
$
$
46
(321)
(275)
$
$
460
(372)
88
December 31,
2019
Movement
December 31,
2018
Plant and equipment
Accounts payable and accrued liabilities
Intangibles
Income deferred for tax purposes
Finance leases
Net deferred tax asset (liability)
$
$
(519)
268
709
(1,496)
763
(275)
$
$
(259)
(58)
513
(626)
67
(363)
$
$
(260)
326
196
(870)
696
88
E. Unrecognized deferred tax assets
Deferred tax assets have not been recognized in respect of certain items. The Company is evaluating
alternatives under which sufficient future taxable profit will be available against which the Company can
use the benefits therefrom. Deductible temporary differences represent costs incurred by the Company
related to the acquisition and charged directly to equity.
Deductible temporary differences
Tax losses
2019
Gross amount
14,321
$
1,021
15,342
$
$
$
The tax losses of $1,021 will expire in 2039.
F. Uncertainty over income tax treatments
2018
Tax effect
Gross amount
-
-
-
3,795 $
271
4,066 $
Tax effect
$
$
-
-
-
The Company believes that its accruals for tax liabilities are adequate for all open tax years based on its
assessment of many factors, including interpretations of tax law and prior experience.
Page | 30
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
18. Leases
The Company leases buildings and equipment in the operation of its Transportation and Logistics businesses.
The Company estimated its incremental borrowing rates for portfolios of leases with similar characteristics, such
as similar risk profiles, same or similar types of security, and similar lease terms. Building lease terms range from
5 to 10 years. Facilities lease liabilities are calculated using the Company’s incremental borrowing rate based on
the specific lease commitments and term for each facility. The average incremental borrowing rate for all
facilities in 2019 is 3.75% (2018 – 3.69%). Equipment lease terms range from 1 to 5 years. Equipment lease
liabilities are calculated using the operating segment’s average incremental borrowing rate on an equipment
lease portfolio basis for that year. The average incremental borrowing rate for equipment in 2019 is 4.07% for
Specialized Transportation and 3.95% for Healthcare Logistics (2018 – 4.66% Specialized Transportation, 4.37%
Healthcare Logistics).
Right of use assets – Facilities
Opening balance
Add: additions
Less: depreciation
Ending balance
Right of use assets – Logistics and transportation
equipment
Opening balance
Add: additions
Less: depreciation
Ending balance
Net carrying amounts of right-of-use assets
Facilities
Logistics and transportation equipment
Balance
December 31,
2019
December 31,
2018
$
$
49,634
17,708
(11,057)
56,285
$
$
51,871
7,623
(9,860)
49,634
December 31,
2019
December 31,
2018
$
$
25,400
11,145
(8,527)
28,018
$
$
21,788
11,215
(7,603)
25,400
December 31,
2019
December 31,
2018
$
$
56,285
28,018
84,303
$
$
49,634
25,400
75,034
Page | 31
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
18. Leases (continued)
Lease liabilities – Facilities
Opening balance
Add: additions
Add: interest expense
Less: repayments
Less: interest payments
Ending balance
Lease liabilities – Logistics and transportation equipment
Opening balance
Add: additions
Add: interest expense
Less: repayments
Less: interest payments
Ending balance
Cash lease principal payments
Repayments of lease principal
Pre-payment of leases
Total lease payments
Lease liabilities
Facilities
Logistics and transportation equipment
Balance
Lease liabilities included in consolidated balance
sheets
Current
Non-current
Balance
Maturity analysis for lease liabilities -
contractual undiscounted cash flows
Less than one year
One to 5 years
More than 5 years
Total undiscounted lease liabilities
December 31,
2019
December 31,
2018
$
$
53,927
17,583
2,238
(10,562)
(2,238)
60,948
$
$
55,394
7,506
2,205
(8,973)
(2,205)
53,927
December 31,
2019
December 31,
2018
$
$
25,093
11,146
1,019
(8,474)
(1,019)
27,765
$
$
21,605
11,215
828
(7,727)
(828)
25,093
December 31,
2019
December 31,
2018
$
$
19,036
125
19,161
$
$
16,700
117
16,817
December 31,
2019
December 31,
2018
$
$
(60,948) $
(27,765)
(88,713) $
(53,927)
(25,093)
(79,020)
December 31,
2019
December 31,
2018
$
$
(19,129) $
(69,584)
(88,713) $
(17,940)
(61,080)
(79,020)
December 31,
2019
December 31,
2018
$
$
22,407
58,882
19,092
100,381
$
$
20,798
51,003
19,120
90,921
Amounts recognized in the consolidated statements of income and comprehensive income in connection with
interest expense for lease liabilities in 2019 was $3,257 (2018 – $3,033). Total cash outflow for leases for 2019
was $22,418 (2018 – $19,850).
Page | 32
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
19. Non-controlling interests
On June 13, 2019, the outstanding equity interests in Associated Logistics Solutions Inc. were purchased from
Bourbon Street Enterprises Inc., reducing the non-controlling interest ownership percentage from 15% to nil.
The carrying amount of NCI purchased at the time of the transaction was $6,489, after giving effect to income
attributable to NCI for the period of $572. As the transaction was with the ultimate parent the transaction has
reduced NCI by $6,489 and increased net parent investment by the same amount.
On July 19, 2018, 15% of the equity interest in Associated Logistics Solutions Inc. was purchased from Bourbon
Street Enterprises Inc. reducing Bourbon Street Enterprises Inc.’s NCI from 30% to 15% of Associated Logistics
Solutions Inc. The carrying amount of NCI purchased at the time of the transaction was $5,600. As the
transaction was with the ultimate parent the transaction has reduced NCI by $5,600 and increased net parent
investment by the same amount.
The following table summarizes the information relating to the Company’s subsidiary that had a material NCI,
before any intercompany eliminations in 2018.
December 31, 2018
NCI percentage
Non-current assets
Current assets
Non-current liabilities
Current liabilities
Net Assets
Net assets attributable to NCI
Revenue
Net Income
Net income allocated to NCI
Dividends paid to NCI
Cash flows from operating activities
Cash flows used in investment activities
Cash flows used in financing activities
$
$
Associated
Logistics
Solutions Inc.
15%
69,838
22,050
40,109
12,333
39,446
5,917
104,941
6,429
1,462
(150)
18,186
(1,145)
(15,651)
Net increase in cash and cash equivalents
$
1,390
Page | 33
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
20. Commitments and contingencies
(i) The Company is, from time to time, involved in claims, legal proceedings and complaints arising in the
normal course of business and provisions for such claims have been recorded where appropriate. The
Company does not believe the final determination of these claims will have an adverse material effect on
its consolidated financial statements.
(ii) As at December 31, 2019, the Company had outstanding letters of guarantee in the amount of $180
(2018 - $68).
(iii) On November 28, 2019, the Company entered into a lease agreement related to a facility located at 200
Edgeware Road, Brampton, Ontario for a 7-year lease term commencing on July 1, 2020. Total lease
commitments over 7 years is $15,450. In relation to the same property, on November 28, 2019, the
Company entered into a construction agreement with Orlando Corporation Inc. (Contractor) and Stevron
Holdings Limited (Landlord) committing to construction work of $2,484, of which the landlord has provided
$1,200 in cash allowances, received in January 2020. Construction is expected to be completed by June
2020.
(iv) The Company has made commitments for Fleet equipment, with the terms to begin upon delivery of the
equipment in 2020. Commitments range from 60 to 84 months and total $2,987.
21. Related parties
During the year, the Company entered into transactions with related parties that were incurred in the normal
course of business. The Company’s policy is to conduct all transactions and settle all balances with related
parties on market terms and conditions. All outstanding balances with these related parties are to be settled in
cash within two months of the reporting date. None of the balances is secured. No expense has been recognized
in the current year or prior year for bad or doubtful debts in respect of amounts owed by related parties.
The Company is indirectly controlled by Michael Andlauer, the President and Chief Executive Officer and CODM.
Included in these consolidated financial statements are the following transactions and balances with companies
related either directly or indirectly to Mr. Andlauer.
Andlauer Management Group Inc. (“AMG”) provides key management personnel to the Company for which it
receives management fees. The Company recovers certain facilities lease costs from AMG. The Company also
provides certain shared services (primarily accounting services) to AMG.
Andlauer Properties and Leasing Inc. (“APLI”) is a subsidiary of AMG and leases certain facilities and logistics and
transportation equipment to the Company. The Company also leases facilities and logistics and transportation
equipment from arm’s length providers. The Company provides certain shared services (primarily accounting
services) to APLI.
9143-5271 (“9143”) Quebec Inc. is a subsidiary of AMG and leases a facility in Quebec to the Company. The
Company provides certain shared services (primarily accounting services) to 9143.
Ready Staffing Solutions Inc., a company owned by Mr. Andlauer’s spouse, provides the Company with
temporary agency employee services – providing hourly dock labour for handling operations, principally in the
GTA. The Company also purchases temporary agency employee services from arm’s length providers.
Page | 34
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
21. Related parties (continued)
1708998 Ontario Limited (Medical Courier Services) (“MCS”) is a subsidiary owned 80% by AMG and provides
transportation services to the Company, providing extended reach for shipments where the Company does not
have facilities or equipment. The Company also provides certain shared services (primarily accounting services)
to MCS.
McAllister Courier Inc. is a subsidiary owned 50% by AMG and provides transportation services to the Company,
providing extended reach for shipments where the Company does not have facilities or equipment.
TDS Logistics Ltd. (“TDS”) is a subsidiary owned 50% by AMG and provides transportation services to the
Company, providing additional capacity where the Company can sub-contract deliveries to take advantage of
coincidences of delivery. Similarly, the Company provides transportation services to TDS. The Company also
provides certain shared services (primarily accounting services) to TDS and recovers certain lease costs from
TDS.
Med Express is a subsidiary owned 50% by AMG and provides transportation services to the Company, providing
extended reach for shipments where the Company does not have facilities or equipment.
D.C. Racking and Maintenance Inc. is a subsidiary of Bourbon Street Enterprises Inc. (“BSE”), a related party
representing the non-controlling interest in Associated Logistics Solutions Inc. It provides maintenance and
repairs for the Company’s Healthcare Logistics segment.
Logiserv Inc. provides the Company with warehouse racking. Logiserv is a subsidiary of BSE. The Company also
purchases warehouse racking from arm’s length providers.
C-GHBS Inc. is a subsidiary of AMG and provides air travel services to the Company.
Bulldog Hockey Inc. is a subsidiary of AMG and provides sports and entertainment services to the Company.
Page | 35
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
21. Related parties (continued)
December 31,
2019
December 31,
2018
Revenue
Transportation services
TDS Logistics Ltd.
1708998 Ontario Limited (Medical Courier Services)
Facility rent recovery
TDS Logistics Ltd.
Andlauer Management Group Inc.
Shared service recovery
TDS Logistics Ltd.
Andlauer Properties and Leasing Inc.
Andlauer Management Group Inc.
9143-5271 Quebec Inc.
1708998 Ontario Limited (Medical Courier Services)
Equipment rental recovery
TDS Logistics Ltd.
Expenses
Transportation services
McAllister Courier Inc.
1708998 Ontario Limited (Medical Courier Services)
TDS Logistics Ltd.
Contract labour services
Ready Staffing Solutions Inc.
Equipment rent
Andlauer Properties and Leasing Inc.
Shared services
Andlauer Management Group Inc.
Facility rent
Andlauer Properties and Leasing Inc.
9143-5271 Quebec Inc.
Sports and Entertainment services
Bulldog Hockey Inc.
Maintenance services
D.C. Racking and Maintenance Inc. and Logiserv Inc.
Travel services
C-GHBS Inc.
Capital expenditures
$
$
721
7
656
320
252
18
12
30
12
364
972
253
558
4,153
1,484
670
605
1,149
25
46
329
100
4
139
-
144
18
12
30
12
-
1,053
236
-
4,176
1,046
696
345
1,109
28
64
-
Purchases of logistics and transportation equipment
Logiserv Inc.
335
177
Page | 36
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
21. Related parties (continued)
Trade receivables due from related parties
Andlauer Management Group Inc.
TDS Logistics Ltd.
Andlauer Properties and Leasing Inc.
9143-5271 Quebec Inc.
Total trade receivables
Due from related parties
Andlauer Management Group Inc.
C-GHBS Inc.
Andlauer Properties and Leasing Inc.
Habdog Investments Inc.
TDS Logistics Ltd.
Total due from related parties
Trade payables due to related parties
Ready Staffing Solutions Inc.
1708998 Ontario Limited (Medical Courier Services)
McAllister Courier Inc.
TDS Logistics Ltd.
Andlauer Properties and Leasing Inc.
Med Express
D.C. Racking and Maintenance Inc.
Logiserv Inc.
Bulldog Hockey Inc.
C-GHBS Inc.
Total trade payables
Due to related parties
M. Andlauer
TDS Logistics Ltd.
Andlauer Management Group Inc.
December 31,
2019
December 31,
2018
$
$
$
$
60
380
-
1
441
53
-
186
-
-
239
680
397
-
71
100
1,196
1
1
69
28
153
2,016
161
174
-
335
2,351
$
$
$
$
$
7
263
113
-
383
52,603
1,405
685
236
28
54,957
55,340
330
24
92
-
32
-
1
70
28
-
577
20
-
300
320
897
Total due to related parties
$
The Company paid management fees of $346 in 2019 (2018 – $576) to Andlauer Management Group Inc. in
connection with compensation for key management personnel.
Page | 37
Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements for the years ended December 31, 2019 and 2018
(In thousands of Canadian dollars, except shares, share price and earnings per share)
22. Capital management
The Company’s policy is to maintain a strong capital base so as to maintain investor, creditor and market
confidence and to sustain future development of the business. Management monitors the return on capital, as
well as the level of dividends and distributions to ordinary shareholders.
The Board of Directors seeks to maintain a balance between the higher returns that might be possible with
higher levels of borrowing and the advantages and security afforded by a sound capital position. The Company
monitors capital using a net leverage ratio, calculated as net debt divided by earnings before interest, taxes,
depreciation and amortization (“EBITDA”). The Company seeks to keep its net leverage ratio below 3.0 in the
ordinary course of business.
Total liabilities
Less: cash and cash equivalents
Net debt
Net income
Interest income
Interest expense
Income tax expense
Depreciation and amortization
EBITDA
Net leverage ratio
23. Subsequent event
December 31,
2019
December 31,
2018
$
$
151,490
(18,712)
132,778
106,849
(53,657)
53,192
30,345
(1,004)
3,503
12,004
25,706
70,554
28,185
(879)
3,048
10,531
23,491
64,376
1.88
0.83
On March 12, 2020, the Board of Directors declared a dividend of $0.06087 per subordinate voting and multiple
voting share, payable on April 15, 2020 to shareholders of record as of March 31, 2020.
Page | 38
Executive Team
Michael Andlauer
Chief Executive Officer
Peter Bromley, CPA, CA
Chief Financial Officer
Stephen Barr
President, Transportation
Bob Brogan
President, Specialty Solutions
Reg Sheen, CPA, CA
President, Logistics
Board of Directors
Peter Jelley
Chair
Andrew Clark 1, 2 *
Lead Director
Michael Andlauer
Director and Chief Executive Officer
Rona Ambrose 1, 2, 3
Director
Cameron Joyce
Director
Joseph Schlett
Director
Evelyn Sutherland, CPA, CA 1, 2, 3
Director
Thomas Wellner 1, 3 *
Director
Independent director
1
2 Member of Compensation, Nominating & Governance Committee
3 Member of the Audit Committee
* Denotes Committee Chair
Shareholder Information
Shares Outstanding
Subordinate Voting Shares (“SVS”): 12,500,000
Multiple Voting Shares: 25,100,000
Registrar and Transfer Agent
TMX Trust Company
Stock Exchange Listing
Andlauer Healthcare Group’s SVS are listed on the
Toronto Stock Exchange under the symbol “AND”
Auditor
KPMG LLP
Legal Counsel
Goodmans LLP
Investor Contacts
Peter Bromley
Chief Financial Officer
T: 416-744-4916
E: Investor.relations@andlauer.ca
Bruce Wigle
Investor Relations
T: 647-496-7856
E: Investor.relations@andlauer.ca
100 Vaughan Valley Blvd.
Vaughan, Ontario
L4H 3C5
www.andlauerhealthcare.com
Platform of Companies